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            PTEN is a master regulator of multiple cellular processes and a potent tumor 
suppressor. Its biological function is mainly attributed to its lipid phosphatase activity 
that negatively regulates the PI3K-AKT signaling pathway. A fundamental and highly 
debated question remains whether PTEN can also function as a protein phosphatase in 
cells. This study demonstrates that PTEN is a protein tyrosine phosphatase that 
selectively dephosphorylates insulin receptor substrate-1 (IRS1), a mediator for 
transduction of insulin and IGF1 signaling.  IGF signaling is defective in cells lacking 
NEDD4, a PTEN ubiquitin ligase, whereas AKT activation triggered by EGF or serum 
is unimpaired in these cells. Surprisingly, the defect of IGF signaling caused by 
NEDD4 deletion, including the of phosphorylation of IRS1, upstream of PI3K, can be 
rescued by PTEN ablation, suggesting PTEN may be a protein phosphatase for IRS1. 
The nature of PTEN as an IRS1 phosphatase is demonstrated by direct biochemical 
analysis and confirmed by cellular reconstitution. Further, we find that NEDD4 
supports insulin-mediated glucose metabolism, and is required for the proliferation of 
IGF1 receptor (IGF1R)-dependent but not EGFR-dependent tumor cells. Taken 
 
 
together, PTEN is a protein phosphatase for IRS1, and its antagonism by the ubiquitin 
ligase NEDD4 promotes IGF/insulin signaling. 
           Finally, we also identified a novel form of PTEN, which is a translational 
variant, termed UPP, and characterized it using biochemical and cellular studies. UPP 
is a fast turnover subpopulation of PTEN, and demonstrates a distinctive subcellular 
localization from PTEN. Co-localization imaging studies indicated that UPP is 
involved in endocytosis membrane trafficking and adherens junctions. UPP still 
functions as a lipid phosphatase for PIP3, antagonizing PI3K signaling. Furthermore, 
UPP was found to be a better binding partner for the PTEN protein substrate, IRS1, in 
cells.  
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CHAPTER ONE 
GENERAL INTRODUCTION 
 
Insulin and IGF signaling pathway 
               Insulin, insulin-like growth factor-1 (IGF1) and insulin-like growth factor-2 
(IGF2) belong to a group of secreted growth factors with essential roles in growth, 
development, and metabolism (Yakar and Adamo, 2012). Insulin and IGF1 are 
structurally homologous growth factors, which function through binding to specific 
receptors (Insulin receptor and IGF1 receptor (IGF1R) respectively) on the surface of 
target cells. The closely related receptors share the same tetrameric structure 
composed of two extracellular α subunits including the ligand-binding domain and 
two transmembrane β subunits containing the tyrosine kinase domain. Binding of 
ligands to α subunits leads to activation and auto-phosphorylation of tyrosine residues 
in the β subunits (Pautsch et al., 2001). Signaling is subsequently mediated by the 
phosphorylation of specific substrates by the activated receptors.   
              The principal substrates for insulin and IGF1 receptors are insulin receptor 
substrate proteins (IRS proteins), which mediate activation of two main downstream 
signaling pathways (White, 1998). After tyrosine phosphorylation at multiple sites, 
IRS1 binds to either the regulatory p85 subunit of phosphatidylinositol 3-kianse 
(PI3K), or the adaptor molecule Grb2, which associates with son-of-sevenless (SOS) 
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to activate the Ras--mitogen-activated protein kinase (MAPK) pathway (Figure 1.1). 
The PI3K-AKT pathway is responsible for most of the metabolic actions of insulin, 
while the MAPK pathway regulates gene expression and cooperates with the PI3K 
pathway to control cell growth and differentiation. 
                PI3K belongs to a conserved family of lipid kinases involving in 
intracellular signaling propagation (Cantley, 2002). PI3K phosphorylates 
phosphatidylinositol-4,5-biphosphate (PIP2) in the plasma membrane to generate 
phosphatidylinositol-3,4,5-triphosphatate (PIP3).  PIP3 is a critical second messenger 
which binds to various signaling proteins containing the pleckstrin homology (PH) 
domains, including the serine/threonine kinase AKT and PDK1 (Manning and Cantley, 
2007). AKT is activated by phosphorylation at T308 in the activation loop by PDK1 
and phosphorylation on the hydrophobic motif S473 by mTOR complex 2 (mTORC2). 
Activated AKT promotes cell survival, growth, proliferation, and inhibit apoptosis, 
through phosphorylating various downstream targets.               
                 The functions of the insulin and IGF components in development were 
demonstrated by mice with genes disrupted by homologous recombination (Taniguchi 
et al., 2006). IGF1R knockout led to the immediate postnatal death from respiratory 
failure, with a dramatic reduction in body weight (more than 50% reduction) (Liu et 
al., 1993). While heterozygous mice are normal, but show a ~15% decrease in body 
mass. In contrast, insulin receptor-disrupted mice are born normal, but develop early 
postnatal diabetes and die of ketoacidosis (Kitamura et al., 2003). IRS1-deficient mice 
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are born alive, but have defective insulin response in the muscle and general 
retardation in body growth due to IGF1 resistance (Liu et al., 1993).  
 
Figure 1.1 
 
IGF and Insulin Signaling Pathways. The binding of growth factors insulin and 
IGF1 to their receptors on cell surface lead to the recruitment of adaptor proteins, 
including SHC and IRS proteins. Tyrosine phosphorylation of IRS promotes binding 
of PI3K and Grb2/SOS, resulting in the activation of the downstream AKT and 
MAPK pathway.  
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               The IRS proteins possess pleckstrin-homolog (PH) domains and 
phosphotyrosine-binding (PTB) domains at the N-terminus that are responsible for the 
high affinity for IR/IGF1R (Boura-Halfon and Zick, 2009). There are up to 20 
potential tyrosine-phosphorylation sites between the center and C-terminus of the IRS 
proteins. After tyrosine phosphorylation by IR/IGF1R, IRS proteins can bind to 
proteins that contain Src-homolog-2 (SH2) domains. Phosphorylation of tyrosines 465, 
612, 632, 662, 941 and 989 of IRS1 YXXM motifs are predicted to bind the SH2 
domain of the p85 regulatory subunit of PI3K, resulting in activation of the p110 
catalytic subunit (Sesti et al., 2001) . Studies have shown that Tyr612 and Tyr632 in 
human IRS1 (corresponding to positions 608 and 628 in rat or mouse IRS1) are 
important for full activation of insulin-stimulated PI3K activity and translocation of 
GLUT4 in adipose cells (Esposito et al., 2001).  
Tumor suppressor PTEN 
            Since its discovery in 1997 (Li and Sun, 1997; Li et al., 1997; Steck et al., 
1997), PTEN (phosphatase and tensin homolog) has been established as one of the 
most frequently mutated tumor suppressor genes in human cancer, including 
endometrial carcinoma, glioblastoma multiforme, skin and prostate cancers (Salmena 
et al., 2008). Biochemically, PTEN is a phosphatase for the lipid second messenger 
PIP3, catalyzing its conversion to PIP2 (Maehama and Dixon, 1998). Therefore, PTEN 
functions as a major regulator of the cellular concentration of PIP3 to antagonize the 
signaling cascades downstream of receptor tyrosine kinases (RTKs) and PI3K ((Figure 
1.2). Interestingly, PTEN might also possess protein phosphatase activity with several 
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potential protein substrates reported (Gu et al., 1999; Mahimainathan and Choudhury, 
2004; Raftopoulou et al., 2004; Tamura et al., 1998).  
            Importantly, PTEN is involved in regulating many cellular processes. Many of 
these functions can be attributed to its lipid phosphatase activity. For example, PTEN 
regulates cell proliferation and apoptosis. These effects are mediated by suppressing 
AKT activation and subsequent alteration of the function of AKT substrates, such as 
forkhead box protein O (FOXO), the E3 ubiquitin ligase Mdm2, and Bcl2 antagonist 
of cell death (BAD) (Tamura et al., 1999).  
            PTEN has a crucial role in regulating the self-renewal and differentiation of 
human embryonic stem cells and hematopoietic stem cells as well as the timing of 
follicle activation through the regulation of oocyte growth (Reddy et al., 2008). PTEN 
also regulates the chemotaxis of neutrophils, and all these functions require its lipid 
phosphatase activity (Heit et al., 2008). Moreover, PTEN can regulate various cellular 
events independently of its lipid phosphatase activity. For example, it can inhibit cell 
cycle progression by modulating the activity of the anaphase promoting 
complex/cyclosome (APC/C) in the nucleus in a manner that is independent of 
PTEN’s enzymatic activity (Song et al., 2011). Furthermore, it can inhibit cell 
invasion and migration, likely through its protein phosphatase activity (Tamura et al., 
1998). PTEN can control the size of DNA-damaged cells by regulating the actin-
remodeling process through a mechanism that is likely independent of its lipid 
phosphatase activity (Kim et al., 2011). Deficiency of any of these functions can 
contribute to tumorigenesis.  
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Figure 1.2 
 
PTEN is the major negative regulator of PI3K-AKT pathway. Physiologically, 
PTEN is a lipid phosphatase for PIP3 at the plasma membrane, antagonizing the 
activity of PI3K. PTEN negatively regulates PIP3 levels, which are essential for AKT 
activation and multiple biological processes.  
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              PTEN contains multiple domains, including an N-terminal phosphatase 
domain, a central C2 domain and a C-terminal tail (Song et al., 2012). The 
phosphatase and C2 domains form a minimal enzymatic unit that is sufficient for 
metabolizing PIP3. The C-terminal tail is a long flexible fragment that is mainly 
involved in PTEN regulation.  
              The functional diversity of PTEN demands a collection of delicate regulatory 
mechanisms, including transcriptional and posttranslational regulation in a tissue- and 
context-dependent manner. The PTEN promoter is regulated by many transcription 
factors, which operate at specific times and in different cell types (Shi et al., 2012). 
PTEN mRNA is susceptible to post-transcriptional regulation by a variety of 
microRNAs (miRNAs), including miR-21, which is the most frequently up-regulated 
onco-miRNA in solid tumors (Meng et al., 2007). Additional complexity results from 
the regulation of PTEN expression by non-coding RNAs, such as the PTEN 
pseudogene PTENP1 mRNA (Poliseno et al., 2010). PTENP1 genetically resembles 
PTEN in its protein coding region. Unlike PTEN mRNA, however, PTENP1 mRNA 
cannot be translated into a protein as a result of a mutation in its initiator codon. The 
PTENP1 mRNA is generally subject to the same miRNA-mediated regulation and thus 
can function as decoys to sequester miR-21. Interestingly, in sporadic colon cancer, 
PTENP1 undergoes a copy number loss that is concurrent with PTEN down-regulation. 
Similarly, ZEB2, another endogenous RNA, was reported to serve as an miRNA 
decoy for the PTEN mRNA, and its loss contributes to melanomagenesis (Karreth et 
al., 2011). However, it is important to bear in mind that only 25% of cancer patients 
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show a correlation between PTEN protein loss and its mRNA level (Chen et al., 2011), 
which emphasizes the importance of PTEN regulation at the posttranscriptional and 
posttranslational levels. 
             PTEN is subject to various posttranslational modifications, including 
phosphorylation, acetylation, oxidation, S-nitrosylation and ubiquitination (Figure 1.3). 
These modifications regulate the enzymatic activity of PTEN, its interaction with 
other proteins and its subcellular localization.  
            Phosphorylation: The first phosphorylation sites mapped on PTEN were a 
cluster of serine and threonine residues in its C-terminal tail (Vazquez et al., 2000). 
Mutation of these residues to alanine leads to elevated membrane affinity, higher 
enzymatic activity and more rapid degradation of PTEN. When these residues are 
phosphorylated, the C-terminal tail can interact with the N-terminal C2 and 
phosphatase domains, which suggests that phosphorylation of the C-terminal tail 
functions as an auto-inhibitory mechanism, controlling both PTEN membrane 
recruitment and lipid phosphatase activity (Odriozola et al., 2007; Rahdar et al., 2009). 
Several kinases have been reported to phosphorylate PTEN. Casein kinase 2 (CK2) 
mainly phosphorylates Ser370 and Ser385 (Torres and Pulido, 2001), whereas 
glycogen synthase kinase 3 beta (GSK3-β) targets Ser362 and Thr366 (Al-Khouri et 
al., 2005). In contrast with the function of C-terminal tail phosphorylation, it seems 
that Thr366 phosphorylation can promote PTEN degradation (Maccario et al., 2007). 
Additionally, glioma tumor suppressor candidate region 2 (GLTSCR2, also known as 
PICT-1) has been shown to interact with PTEN, enhance its phosphorylation at Ser380 
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and stabilize it (Okahara et al., 2006; Yim et al., 2007). Moreover, RhoA-associated 
kinase (ROCK) has been shown to phosphorylate PTEN at Ser229, Thr232, Thr319 
and Thr321, which are all located in the C2 domain, and promote its membrane 
targeting in chemoattractant-stimulated leukocytes (Li et al., 2005). A Src family 
tyrosine kinase, RAK has been reported to interact with PTEN and phosphorylate it on 
Tyr336, thereby protecting it from neural precursor cell expressed, developmentally 
downregulated-4-1 (NEDD4-1)-mediated proteasomal degradation (Yim et al., 2009). 
             Acetylation: Similar to phosphorylation, acetylation can also regulate PTEN 
activity. The histone acetyltransferase p300/CBP-associated factor (PCAF) has been 
reported to interact with PTEN and promote PTEN acetylation on Lys125 and Lys128 
in response to growth factors (Okumura et al., 2006). As these residues are within the 
catalytic pocket, PTEN acetylation by PCAF negatively regulates its enzymatic 
activity. PTEN is also acetylated on Lys402, within the C-terminal PDZ domain-
binding motif Thr–Lyz–Val sequence (Ikenoue et al., 2008). This potentially affects 
the interaction between PTEN and PDZ domain-containing proteins. Nuclear cap-
binding protein (CBP) and the sirtuin SIRT1 have been identified as the major PTEN 
acetyltransferase and deacetylase, respectively. 
           Oxidation: Another mechanism that can potentially regulate the catalytic 
activity of PTEN is direct oxidation by reactive oxygen species (ROS). ROS can 
oxidize Cys124 in the active site, thereby forming an intramolecular disulfide bond 
with Cys71 (Lee et al., 2002). Oxidative inactivation of PTEN has been reported in 
studies using hydrogen peroxide or endogenous ROS production in macrophages 
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(Kwon et al., 2004; Leslie et al., 2003). PTEN activity can also be indirectly inhibited 
by oxidation through modulation of PTEN binding partners. Oxidation of the 
antioxidant DJ-1 (also known as PARK7) leads to its binding to PTEN and the 
subsequent inhibition of the PTEN lipid phosphatase activity (Kim et al., 2009). 
          S-nitrosylation: A few studies have demonstrated the importance of another 
redox mechanism, S-nitrosylation, in the regulation of PTEN. The level of S-
nitrosylation on PTEN substantially increases in the early stages of Alzheimer’s 
disease, and this correlates with reduced PTEN protein levels and elevated AKT 
phosphorylation (Kwak et al., 2010a). Nitrogen Oxide (NO) signaling induces PTEN 
S-nitrosylation, thereby inactivating the lipid phosphatase, down-regulating its protein 
level through NEDD4-1-mediated degradation, and leading to downstream AKT 
activation. Another report has shown that PTEN is selectively S-nitrosylated on Cys83 
by low concentrations of NO (Numajiri et al., 2011). Moreover, S-nitrosylated PTEN 
has been detected in the core and penumbra regions of ischemic mouse brains, likely 
as a protective mechanism to promote AKT activation. 
Ubiquitin ligase NEDD4 
               The modification of ubiquitination is made by sequential transfer of activated 
ubiquitin to substrate protein, involving ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme (E2) and ubiquitin ligase (E3) (Mani and Gelmann, 2005). E3s 
catalyze the transfer of ubiquitin to Lys residues in the substrate and covalent 
conjugation between the carboxyl group of the carboxy-terminal Gly residue of 
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ubiquitin and the ε–amino group of an internal Lys in the substrate, therefore dictating 
the specificity of ubiquitination. A substrate protein can be mono-ubiquitinated at one 
site, multi-ubiquitinated at various residues or poly-ubiquitinated through formation of 
chains of ubiquitin (Ikeda and Dikic, 2008). Usually the fate of the substrate depends 
on the length and architecture of ubiquitin chain. Among the seven Lys residues (K6, 
K11, K29, K33, K48 and K63), Lys 48 and Lys 63 are the most commonly utilized. 
Generally, K48-linked polyubiquitination targets substrates for degradation by the 26S 
proteasome, while monoubiquitination and K63-linked polyubiquitination regulate 
multiple cellular processes, including signal transduction and protein subcellular 
localization (Rotin and Kumar, 2009).  
             NEDD4-1 belongs to one of the two main classes of E3 ligases, HECT 
(Homologous to E6-AP C-Terminus) E3 enzymes (Yang and Kumar, 2010). 
Mammalian NEDD4 contains an N-terminal calcium/lipid and/or protein binding C2 
domain, three (in mouse or rat) or four (in human) WW domains (protein-protein 
interaction domains), and a C-terminal HECT domain (Anan et al., 1998; Kumar et al., 
1997; Staub et al., 1996). The Nedd4 gene was initially identified by a subtraction 
cloning as a transcript which highly expressed in the mouse embryonic brain and 
decreased as development progressed (Kumar et al., 1992). NEDD4 protein is detected 
in various embryonic tissues and widely expressed in mammalian adult tissues. 
NEDD4 protein, around 120 kDa, localizes to the cellular cytoplasm, mainly in the 
perinuclear region and cytoplasm periphery (Anan et al., 1998; Kumar et al., 1997). 
NEDD4 interacts with specific E2 enzymes containing Ubc4, UbcH5B, UbcH5C, 
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UbcH6 and UbcH7 (Anan et al., 1998). Systematic analysis of the types of ubiquitin 
chains showed that NEDD4, with UbcH5, formed exclusively Lys63 ubiquitin chains 
(Kim et al., 2007). 
             Using a biochemical purification approach, NEDD4 was identified as an E3 
ligase that ubiquitinates PTEN (Wang et al., 2007b). NEDD4 physically interacts with 
PTEN and its overexpression leads to both mono- and poly-ubiquitination of PTEN. 
Interestingly, mono-ubiquitination of PTEN appears to be crucial for its nuclear 
import (Trotman et al., 2007). Consistent with the function of the C-terminal tail of 
PTEN in regulating its stability, deletion of this region makes PTEN a stronger 
binding partner and better substrate for NEDD4 (Wang et al., 2008). However, in most 
experimental systems, PTEN appears to be a rather stable protein. Under normal 
growth condition, inhibition of NEDD4 expression does not affect cellular PTEN 
levels or AKT activation in several examined cell types, suggesting that regulation of 
PTEN by NEDD4 might be only relevant under specific biological contexts. For 
example, NEDD4 is required for neuronal axonal branching in retinal ganglion cells 
(RGCs) and mainly functions through down-regulating PTEN (Drinjakovic et al., 
2010). Blocking NEDD4 function severely inhibits terminal branching in RGCs, 
whereas PTEN knockdown rescues the branching deficiency. Also, NEDD4-mediated 
PTEN ubiquitination is essential for regulating PI3K–AKT signaling for neuronal 
survival in response to Zn
2+ 
(Kwak et al., 2010b). Furthermore, in cultured neuronal 
models, NO signaling not only induces PTEN S-nitrosylation but also results in 
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enhanced PTEN protein degradation through NEDD4-mediated ubiquitination (Kwak 
et al., 2010a).  
             Several cellular proteins have been reported to modulate the association 
between NEDD4 and PTEN, which might provide mechanistic insights into the 
context-dependent regulation of PTEN by NEDD4. In breast cancer cells, the tyrosine 
kinase RAK positively regulates PTEN stability by phosphorylating PTEN on Tyr336. 
This prevents PTEN from binding to NEDD4 and its subsequent degradation (Yim et 
al., 2009). The PY (Pro–Pro–x–Tyr)-motif containing membrane proteins NEDD4-
family interacting proteins (NDFIP) 1 and 2, which are potent activators of NEDD4 
family members, were shown to promote NEDD4-mediated ubiquitination and 
degradation of PTEN (Howitt et al., 2012; Mund and Pelham, 2010). 
              Studies investigating the oncogenic activity of NEDD4 in various cell culture 
and mouse models indicate NEDD4 is critical for targeting PTEN for degradation in a 
variety of cancers. Over-expression of NEDD4 promotes oncogenic K-Ras-mediated 
transformation in  p53
-/-
 primary MEFs in soft-agar-colony formation experiments 
(Wang et al., 2007b). Analysis of invasive human bladder cancer samples showed that 
PTEN levels were inversely correlated with the levels of NEDD4. Xenograft mouse 
models using two human prostate cancer cell lines, DU-145 (PTEN positive) and PC3 
(PTEN negative) show that NEDD4 RNAi inhibits tumor growth in a PTEN-
dependent manner. Immunohistochemical analysis on tissue microarrays of non-small 
cell lung carcinoma (NSCLC) revealed NEDD4 over-expression in 80% of tumors, 
which correlated with the loss of PTEN protein (Amodio et al., 2010). Furthermore, 
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inhibition of NEDD4 expression significantly reduces in vitro proliferation of NSLC 
cells and tumor growth in xenografts. Finally, FoxM1, a transcription factor over-
expressed in human glioma tissue, with its expression level correlated with glioma 
grade, up-regulates the expression of NEDD4, promoting PTEN ubiquitination and 
degradation in glioma cells (Dai et al., 2010). 
 
 
Figure 1.3  
 
Post-translational modifications of PTEN. Summary of enzymes and key residues 
of post-translational modification of PTEN.  
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CHAPTER TWO 
FUNCTION OF NEDD4 IN IGF SIGNALING* 
 
INTRODUCTION 
 
             The physiological function of NEDD4 was demonstrated by knockout mice 
studies (Cao et al., 2008; Fouladkou et al., 2008). NEDD4-null mice are small, due to 
delayed embryonic development, severe growth retardation and neonatal lethality, a 
phenotype reminiscent of that observed in mice with deletion of AKT1, IGF1 or 
IGF1R (Cao et al., 2008). Moreover, NEDD4
-/-
 mouse embryonic fibroblasts (MEFs) 
showed decreased IGF1, insulin signaling and reduced mitogenic activity, suggesting 
that NEDD4 is a positive regulator of cell proliferation and animal growth. The 
growth defect of the NEDD4
-/-
 embryos was attributed to a decrease of cell surface 
IGF1R and subsequent IGF1 signaling. Furthermore, there was an increase in the 
protein level of GRB10, an adaptor protein and negative regulator of IGF1 signaling 
(Smith et al., 2007; Wang et al., 2007a), in the NEDD4
-/-
 MEFs.  
             Previous studies showed that PTEN was regulated by ubiquitination and a 
substrate of the NEDD4 ubiquitin ligase (Wang et al., 2007b).  However, under 
normal growth conditions, inhibition of NEDD4 expression does not affect either 
cellular PTEN levels or AKT activation in several examined cell types (Fouladkou et 
*: citation 4 
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al., 2008), suggesting that regulation of PTEN by NEDD4 might be only relevant 
under specific biological contexts (Shi et al., 2012). 
              In this study, we sought to investigate whether insulin and IGF signaling 
required NEDD4-mediated PTEN suppression. By conducting both cellular and in 
vitro biochemical analysis, we discovered that suppression of PTEN by NEDD4 
played a physiologic role in maintaining AKT activation induced specifically by IGFs 
but not by other tested agonists. Consistent with this function, NEDD4 regulated 
IGF1R-dependent cancer cell growth and insulin-mediated glucose metabolism. 
 
RESULTS 
 
NEDD4 is required for IGF/insulin signaling but not EGF signaling 
          We found that in NEDD4
-/-
 MEFs, activation of AKT phosphorylation in 
response to IGF1 or insulin was greatly diminished compared to paired NEDD4
+/+
 
MEFs, whereas induction of AKT phosphorylation by serum or EGF was intact in 
NEDD4
-/-
 MEFs (Figure 2.1A). Similar to IGF1, IGF2 cannot stimulate AKT 
phosphorylation in NEDD4
-/- 
MEFs, though IGF2-induced AKT activation is normal 
in NEDD4
+/+
 MEFs (Figure 2.1B). Consistently, NEDD4 deletion did not abrogate 
EGF signaling when different doses of EGF were used to trigger the pathway (Figure 
2.1C). Even though EGF-induced AKT phosphorylation was comparable in both 
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MEFs, EGFR phosphorylation was slightly higher in NEDD4
-/- 
MEFs. To further 
confirm the effect of NEDD4 in IGF signaling, we engineered wild type (WT) MEFs 
to express two different shRNA sequences against NEDD4 in a doxycycline (Dox)-
inducible manner. Time course analysis of the cell lines showed that Dox caused 
marked reduction of NEDD4 expression within 2 days but little change of PTEN or 
Grb10 protein levels (Figure 2.2A). Similar to data from NEDD4 knockout MEFs, 
Dox-induced depletion of NEDD4 protein suppressed the ability of IGF1 to induce the 
phosphorylation of both AKT and tyrosine phosphorylation on upstream IRS1 (Figure 
2.2B). 
            The kinetics of signaling by IGF1, insulin and EGF were then examined in 
more detail. In WT MEFs, IGF1 rapidly induced the phosphorylation of IGF1R and 
IRS1, which persisted without decline for at least 60 minutes (Figure 2.3A). This was 
associated with a potent and equally persistent induction of AKT phosphorylation. 
After Dox-induced NEDD4 knockdown, although IGF1R phosphorylation was 
unaffected, induction of IRS1 phosphorylation at Y608 5 minutes after IGF1 
stimulation was significantly repressed and remained so up to 60 minutes later. This 
was accompanied by markedly reduced induction of AKT phosphorylation. Insulin 
signaling was similarly defective after NEDD4 knockdown, though phosphorylation 
of Insulin receptor was intact (Figure 2.3B). In contrast, NEDD4 knockdown had no 
effect on the magnitude or kinetics of the induction by EGF of phosphorylation of 
EGFR or AKT (Figure 2.3C). Thus, NEDD4 was specifically required for induction of 
the PI3K/AKT pathway by IGF1 and insulin but not by EGF or serum. 
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Figure 2.1  
 
NEDD4 specifically regulates IGF/insulin signaling but not EGF or serum 
signaling. (A) IGF1 and insulin signaling but not EGF or serum signaling is defective 
in NEDD4
-/-
 MEFs. NEDD4
+/+ 
and NEDD4
-/-
 MEFs were serum-starved for 3 hrs, and 
then stimulated with either 50 ng/ml IGF1, 100 ng/ml Insulin, 10% serum or 100 
ng/ml EGF for 5 min. (B) IGF2 signaling is defective in NEDD4
-/-
 MEFs. NEDD4
+/+ 
and NEDD4
-/-
 MEFs were serum starved for 3 hrs, then stimulated with either 10% 
serum, 50 ng/ml IGF1 or 50 ng/ml, 100 ng/ml IGF2 for 5 min. (C) Dose response of 
EGF showing NEDD4 is not required for EGF signaling. NEDD4
+/+ 
and NEDD4
-/-
 
MEFs were serum-starved for 3 hrs, and then stimulated with either insulin (100 ng/ml) 
or EGF (1, 5 or 20 ng/ml as indicated) for 5 min. 
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Figure 2.2  
 
Inducible NEDD4 RNAi blocks IGF1 signaling. (A) Analysis of WT MEFs with 
Dox-inducible NEDD4 shRNA. WT MEFs harboring non-targeting (NT) and Dox-
inducible NEDD4 shRNA constructs (shN4-A or shN4-B) were treated with or 
without 1 g/ml Dox for indicated time. (B) Inducible NEDD4 RNAi blocks IGF1 
signaling. WT MEFs harboring Dox-inducible NEDD4 shRNA constructs (shN4-A or 
shN4-B) were treated with or without 1 g/ml Dox for 3 days, serum-starved for 3 hrs, 
and then stimulated with 50 ng/ml IGF1 for 5 min.  
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Figure 2.3  
 
Kinetic analysis of the effect of NEDD4 elimination on IGF/insulin/EGF signaling. 
(A) Time course showing NEDD4 RNAi ablates IGF1 signaling. MEFs harboring a 
Dox-inducible NEDD4 shRNA construct were treated with or without 1 µg/ml Dox 
for 3 days, serum-starved for 3 hrs, and then stimulated with 50 ng/ml IGF1 for the 
indicated time. (B) Time course showing NEDD4 RNAi ablates insulin signaling. 100 
ng/ml Insulin was used for indicated time after 3 hrs of serum starvation. (C) Time 
course showing NEDD4 RNAi does not block EGF signaling. 100 ng/ml EGF was 
used for indicated time after 3 hrs of serum starvation. 
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The role of NEDD4 in IGF signaling is PTEN-dependent 
 
             In NEDD4-deficient cells, ligand activation of IGF1R and insulin receptor 
was normal, as monitored by the induction of their tyrosine phosphorylation. For 
IGF1R, both its early phosphorylation at Y1135/1136 (Pautsch et al., 2001) and that at 
the juxtamembrane Y980 site  were not inhibited by NEDD4 deletion (Figure 2.4A). 
However, induction of both IRS1 and AKT phosphorylation was defective when 
NEDD4 was absent. 
             Because NEDD4 is an E3 ubiquitin ligase for PTEN, we examined whether 
the requirement of NEDD4 for IGF/insulin signaling was due to its suppression of 
PTEN function. Indeed, when PTEN was knocked down in NEDD4
-/- 
MEFs by two 
different Dox-inducible shRNA constructs, IGF1-induced IRS1 phosphorylation and 
AKT phosphorylation were restored, with no effect on IGF1R phosphorylation (Figure 
2.4B). To rule out the possibility of off-target effects of RNAi, we introduced back 
shRNA-resistant PTEN for rescue experiments. Indeed, expression of shRNA-resistant 
PTEN in the NEDD4
-/-
 MEFs, consistently prevented rescue of IGF1-induced AKT 
activation by PTEN shRNA (Figure 2.4C). These data suggested that NEDD4 enabled 
IGF signaling by suppressing PTEN function.  
            To determine how NEDD4 regulates PTEN upon IGF1 treatment, first, we 
tested if IGF1 addition could increase the interaction between NEDD4 and PTEN by 
co-immunoprecipitation (Co-IP) experiments. Interestingly, endogenous PTEN 
interacted with endogenous NEDD4 constitutively (Figure 2.5A). To explore the 
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possible mechanisms by which PTEN regulated IRS1 phosphorylation in a NEDD4-
sensitive manner, we tested whether PTEN interacted with IRS1. As shown in Figure 
2.5B, S-tagged PTEN interacted with exogenous IRS1 in 293T cells and this 
interaction was blocked by over-expression of wild-type but not enzymatically 
inactive NEDD4, suggesting NEDD4 inhibited the interaction between PTEN and 
IRS1 through its E3 ligase activity. 
               However, we did not observe changes in gross PTEN protein expression 
when NEDD4 expression was knocked down in MEFs or when cells were stimulated 
with IGF1. So what was the precise mechanism by which NEDD4 regulated PTEN in 
response to IGF/insulin stimulation? Previous systematic analysis of the types of 
ubiquitin chains showed that NEDD4 in collaboration with E2, UbcH5, formed 
homogenous chains exclusively Lys63 chains (Kim et al., 2007). So we tested if 
PTEN polyubiquitination by NEDD4 was through K48 or K63 chain, in vitro PTEN 
ubiquitination assay. Employing various ubiquitin mutants, we confirm that NEDD4 
mainly formed K63-specific polyubiquitination chain on PTEN in vitro (Figure 2.6), 
suggesting suppression of PTEN by NEDD4 was probably through mechanisms other 
than proteasomal degradation, which is exclusively mediated through K48 
polyubiquitination chains.  
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Figure 2.4  
 
NEDD4 functions through PTEN in IGF1 signaling pathway. (A) IGF1-induced 
AKT and IRS1 phosphorylation, but not IGF1R phosphorylation, is defective in 
NEDD4
-/-
 MEFs. NEDD4
+/+ 
and NEDD4
-/-
 MEFs were serum-starved for 3 hrs, and 
then stimulated with 50 ng/ml IGF1 for indicated time. Activation of IGF1R, IRS1, 
and AKT was monitored by using indicated antibodies. (B) Inducible PTEN RNAi 
restores IGF1 signaling in NEDD4
-/-
 MEFs. NEDD4
-/-
 MEFs harboring inducible 
PTEN shRNA constructs (shPTEN-A or shPTEN-B) were treated with or without 1 
µg/ml Dox for 3 days, serum-starved for 3 hrs, and then stimulated with 50 ng/ml 
IGF1 for indicated time. (C) shRNA-resistant PTEN counters the effect of PTEN-
shRNA in NEDD4
-/-
 MEFs. NEDD4
-/-
 MEFs harboring inducible PTEN shRNA were 
reconstituted with either GFP or shRNA-resistant GFP-PTEN, and then subjected to 
serum-starvation followed by 50 ng/ml IGF1 stimulation for 5 min. o/e: 
overexpression. SC: scramble. 
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Figure 2.5  
 
NEDD4 inhibits interaction between PTEN and IRS1. (A) PTEN interacts with 
NEDD4 constitutively in MEFs.  WT MEFs were treated as indicated, and then 
endogenous PTEN was immunoprecipitated by PTEN antibody. (B) NEDD4 inhibits 
the interaction between PTEN and IRS1 in a NEDD4 E3 ligase activity-dependent 
manner. 293T cells were co-transfected with vector or S-tagged PTEN (PTEN-S) and 
indicated NEDD4 plasmids. The cell lysates were immunoprecipitated with S-agarose 
and followed by immunoblotting for PTEN and IRS1. 
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Figure 2.6 
 
NEDD4 forms K63-specific polyubiquitination chain on PTEN. Purified 
recombinant PTEN protein was mixed with WT or ubiquitin mutants in PTEN 
ubiquitination assay. Assays were allowed to process for indicated time.  
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The effect of NEDD4 on the biological function of IGF/insulin signaling 
 
                 To investigate the impact of NEDD4 on the biological functions of 
IGF/insulin signaling, we first asked whether the requirement of NEDD4 in 
IGF1/insulin signaling had any effect on cell growth. Interestingly, we noticed that 
NEDD4 RNAi in WT MEFs led to decrease in basal IRS1 tyrosine phosphorylation, 
even though PTEN levels did not change (Figure 2.7A). Some cancer cells require 
IGF1R activity for the maintenance of proliferation, including the Ewing’s sarcoma 
cell line TC71 and the breast cancer cell line MCF7 (both PTEN-positive). Using 
pharmacologic inhibitors for IGF1R (OSI-906) and EGFR (erlotinib), we confirmed 
that IGF1R activity but not EGFR activity was required for maintaining AKT 
activation in TC71 (Figure 2.7B). By contrast, non-small cell lung cancer cell line PC9 
(PTEN-positive), which contained an activating mutant of EGFR, was dependent on 
EGFR signaling but not IGF1R signaling (Figure 2.7B). Similarly, we validated that 
IGF1R, but not EGFR, activity was required for maintaining AKT activation in MCF7 
(Figure 2.7C). However, breast cancer cell line MDA-MB468 (PTEN-negative) was 
dependent on neither (Figure 2.7C). Consistently, RNAi knockdown of NEDD4 also 
blocked AKT activation and upstream IRS1 tyrosine phosphorylation in TC71 (Figure 
2.7D). And NEDD4 was dispensable for AKT activation in PC9 cells (Figure 2.7E). 
NEDD4 RNAi caused a decrease in AKT phosphorylation in MCF7 while MDA-MB-
468 did not require NEDD4 expression for AKT activation (Figure 2.7F). 
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           NEDD4 was also selectively required for the proliferation of TC71 cells. In the 
IGF1R-dependent TC71 cells, NEDD4 knockdown potently reduced cell proliferation 
(Figure 2.8A), whereas in PC9 cells, NEDD4 knockdown had no discernible effect 
(Figure 2.8B). 
             Because insulin signaling was a major physiological regulator of glucose 
metabolism (Kitamura et al., 2003), NEDD4 could also be involved in glucose 
metabolism. For this reason, we examined the effect of NEDD4 knockdown on 
insulin-regulated glucose metabolism in MEFs. As expected, elimination of NEDD4 
by Dox-induced RNAi significantly reduced glucose uptake (Figure 2.9A) and 
associated lactate production (Figure 2.9B), whereas glutamine uptake (Figure 2.9C) 
and associated glutamate production (Figure 2.9D) were not affected. 
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Figure 2.7 
 
NEDD4 is required for AKT activation of IGF1R-dependent tumor cells. (A) 
NEDD4 RNAi effect on basal p-IRS1 in MEFs. (B) AKT activation in TC71 requires 
IGFR but not EGFR, while AKT activation in PC9 cells requires EGFR but not IGFR. 
TC71 cells were treated with either 5 µM IGF1Ri or 5 µM EGFRi for 1 hr. PC9 cells 
were treated with either 5 µM IGF1Ri or 5 µM EGFRi for 24 hrs. (C) The effect of 
IGF1R inhibitor, EGFR inhibitor on AKT activity in MCF7 and MDA-MB-468 cells. 
MCF7 and MDA-MB-468 cells were treated with either 5 µM IGF1Ri or 5 µM EGFRi 
for 3 hrs. (D) Dox-inducible NEDD4 RNAi blocks AKT activation in TC71 cells. (E) 
Dox-inducible NEDD4 RNAi does not block AKT activation in PC9 cells. NT: non-
targeting shRNA. (F) The effect of NEDD4 RNAi on AKT activity in MCF7 and 
MDA-MB-468 cells. 
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Figure 2.8 
 
NEDD4 is required for growth of IGF1R-dependent tumor cells. (A) Dox-
inducible NEDD4 RNAi inhibits proliferation of TC71 cells. TC71 cells expressing 
indicated shRNA constructs were seeded for cell growth assay and colony formation 
assay, in the presence of 1µg/ml Dox. (B) Dox-inducible NEDD4 RNAi does not 
inhibit proliferation of PC9 cells. PC9 cells expressing indicated shRNA constructs 
were seeded for cell growth assay and colony formation assay in the presence of 
1µg/ml Dox.  
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Figure 2.9  
 
NEDD4 regulates insulin-induced glucose metabolism. MEFs harboring Dox-
inducible NEDD4 shRNA were cultured in the absence or presence of Dox as 
indicated. Cells were serum starved for 6 hrs and then incubated in serum-free 
medium containing 200 ng/ml insulin for 18 hrs. Media were taken from each 
culturing condition to measure glucose uptake (A), lactate production (B), glutamine 
uptake (C), and glutamate production (D). Error bars indicate standard deviation from 
multiple independent experiments (“*”: p<0.05). 
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DISCUSSION 
 
              In this study, we demonstrated that NEDD4 was specifically required for IGF 
and insulin signaling, but not EGF or serum signaling.  By using inducible-RNAi, we 
showed that the function of NEDD4 in maintaining IGF1-induced AKT activation was 
through suppressing PTEN activity. Particularly we pinpointed that NEDD4 blocked 
the interaction between IRS1 and PTEN, and this was dependent on its ubiquitin E3 
ligase activity.  Furthermore, the impact of NEDD4 on the biological functions of 
IGF/insulin signaling was defined by the results that NEDD4 regulated IGF1R-
dependent cancer cell growth and insulin-mediated glucose metabolism.  
                   This work is conceptually important for our general understanding of RTK 
signaling. Diverse growth factors function by activating their corresponding RTKs, 
which stimulate a variety of downstream signaling programs, including those mediated 
by PLC, STAT phosphorylation, RAS and PI3K-AKT pathways (Casaletto and 
McClatchey, 2012). The variety of proliferative RTK pathways might provide 
differential nodes for regulation. However, the mechanisms that enable specificity of 
signaling through these pathways and how specific receptors mediate very different 
biologic effects remains poorly understood. The observation that NEDD4 was 
specifically required for IGF signaling but not EGF signaling provides mechanistic 
insights into how various RTK pathways could be distinctly regulated even though 
they all function through common downstream effector molecules. Interestingly, 
IGF1R and Insulin Receptor require adaptor IRS proteins to mediate the binding to 
downstream effectors, unlike other RTKs which bind directly to downstream effectors 
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(Taniguchi et al., 2006). The specific requirement of NEDD4 in IGF and Insulin 
signaling could be attributed to the effects of NEDD4 on IRS1 tyrosine 
phosphorylation. 
             By inhibiting the activity of PTEN, NEDD4 could contribute to the effects of 
insulin and IGFs on multiple important physiological processes, including growth, 
metabolism, and glucose homeostasis (Engelman et al., 2006). Further, because 
NEDD4 has other protein substrates such as RNA polymerase II (Anindya et al., 2007), 
Cbl-b (Yang et al., 2008), and Activated Cdc42-associated tyrosine kinase (Lin et al., 
2010), this ubiquitin ligase might possess additional biological functions independent 
of PTEN or IGF/insulin signaling (Persaud et al., 2009). Very recently, NEDD4 was 
reported to interact, ubiquitinate and degrade Ras, playing a role in Ras-driven 
tumorigenesis (Zeng et al., 2014). This might help explain why NEDD4 was not 
required for proliferation of EGFR-dependent cancer cell lines.   
               It has been reported that NEDD4 deficiency leads to the internalization and 
degradation of IGF1R or insulin receptors, hours after agonist stimulation (Cao et al., 
2008). While such a NEDD4-regulated receptor desensitization mechanism might play 
a role in the later stages of IGF/insulin signaling, it does not provide an explanation 
for the involvement of PTEN, neither does it account for the rapid inhibition of IRS1 
and AKT activation by NEDD4 elimination, which could be observed as early as 5 
min after agonist stimulation. Further, NEDD4 elimination only blocked activation of 
IRS1 and AKT but not that of IGF1R or insulin receptor, indicating that even in the 
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absence of NEDD4, receptors were available on the cell surface for activation by their 
agonists at early time points.  
              However, the precise mechanism by which NEDD4 regulated PTEN in 
response to IGF/insulin stimulation was not clear at this stage. We did not observe any 
changes in total PTEN protein level when NEDD4 expression was knocked down in 
MEFs or when cells were treated with IGF1 or insulin. One possibility is that only a 
small subpopulation of total PTEN is required to suppress IGF signaling, and that 
NEDD4 selectively antagonizes this sub-fraction. In line with this possibility, it was 
recently reported that NEDD4 preferentially ubiquitinates membrane-localized PTEN, 
and that PTEN ubiquitination is sufficient to suppress its phosphatase activity even in 
the absence of proteasomal degradation (Maccario et al., 2010).  It is also possible that 
insulin-stimulated production of reactive oxygen species (ROS) could contribute to 
this process, as PTEN modified by ROS has been shown to be a better substrate for 
NEDD4 (Kwon et al., 2004).  Furthermore, a recent paper reported that NEDD4 
mediates K63-specific polyubiquitination on PTEN during T cell activation and lysine 
13 was the major ubiquitination site for PTEN (Guo et al., 2012).  We also showed 
that NEDD4 forms K63-specific, and not K48-specific, polyubiquitination chains on 
PTEN in vitro. Therefore, we hypothesize that IGF stimulus promotes PTEN K-63 
polyubiquitination, subsequently inhibiting PTEN activity.  
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CHAPTER THREE 
 PTEN IS A PROTEIN TYROSINE PHOSPHATASE FOR IRS1* 
 
INTRODUCTION 
 
            PTEN is a physiological lipid (PIP3) phosphatase but may also possess protein 
phosphatase activity. The protein tyrosine phosphatase activity of PTEN has been 
suggested based on its domain structure (Lee et al., 1999; Li and Sun, 1997) and on 
the observation that PTEN could dephosphorylate synthetic phosphor-tyrosine 
peptides (Myers et al., 1997). Additionally, it has been suggested that such protein 
phosphatase activity may be relevant to various functions of PTEN, such as cell 
migration and invasion (Maier et al., 1999; Tamura et al., 1999; Tibarewal et al., 2012; 
Zhang et al., 2012). However, no phosphoprotein substrates of PTEN have been 
conclusively identified in vivo. Therefore, whether PTEN is a physiologically relevant 
protein phosphatase remains an open question.  
            In MCF7 breast cancer cells, overexpression of WT PTEN resulted in general 
inhibition of AKT activation stimulated by various growth factors, but selective 
inhibition of MEK/ERK phosphorylation induced by insulin and IGF1(Weng et al., 
2001). These data suggested that PTEN could block insulin-stimulated IRS1 
phosphorylation and IRS1/Grb2/Sos complex formation. Interestingly, loss of PTEN 
correlated specifically with a suppression of IGF1/insulin signaling in a number of cell 
*: citation 4 
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lines, but had no effect on platelet-derived growth factor (PDGF) or EGF signaling 
(Lackey et al., 2007). This phenotype could be partially explained by reduced protein 
levels of IRS1, IGF1R and insulin receptor.  
          Our previous studies in chapter one showed that PTEN could interact with IRS1 
and regulated IRS1 tyrosine phosphorylation. Using biochemical and cellular studies, 
we tested if IRS1 was a direct protein substrate of PTEN.  
 
RESULTS 
 
PTEN is a protein tyrosine phosphatase for IRS1 in vitro 
 
             To address this question, we engineered WT MEFs expressing PTEN shRNA, 
and then reconstituted these cells by expressing RNAi-resistant GFP-S-tagged wild-
type (WT) PTEN, C124S (CS) mutant PTEN, or G129E (GE) mutant PTEN. CS 
mutant PTEN is defective in total enzymatic activity, while GE mutant PTEN cannot 
dephosphorylate lipid substrates, such as PIP3, but maintains protein phosphatase 
activity, and can still dephosphorylate synthetic peptides containing phospho-tyrosine. 
As shown in Figure 3.1A, PTEN RNAi caused a substantial increase of basal p-AKT, 
and introducing back WT PTEN, but not CS or GE mutants, inhibited the elevation of 
pAKT. This conclusion was also validated in cells with EGF treatment. WT PTEN but 
not the CS or GE mutants could inhibit EGF-induced AKT phosphorylation (Figure 
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3.1B). This conclusion was further validated in cells lacking PTEN: WT PTEN but not 
the CS or GE mutants could inhibit cellular PIP3 production in PTEN-negative PC3 
cells (Figure 3.1C). 
            We generated purified recombinant WT PTEN protein, CS PTEN mutant 
protein, and GE PTEN mutant protein (Figure 3.2A). Their lipid phosphatase activities 
were confirmed by an in vitro lipid assay that confirmed WT PTEN, but not the CS or 
GE mutants, could dephosphorylate PIP3, even though the concentrations of CS or GE 
mutant proteins were 100 times that of WT PTEN (Figure 3.2B). We then generated 
phospho-IRS1 substrate by overexpressing HA-tagged IRS1 and HA-tagged IGF1R in 
293 cells and subsequently treating the cells with IGF1. The IRS1 substrates were 
isolated by immuno-precipitation. When the isolated IRS1 was incubated with 
recombinant PTEN, we observed dephosphorylation of IRS1 in a PTEN dose-
dependent manner, as monitored with a specific antibody against pY608 of IRS1 
(Figure 3.2C). This activity could be blocked by a general protein phosphatase 
inhibitor cocktail (Y inhibitor). Dephosphorylation of IRS1 was a property of the GE 
mutant but not the CS mutant (Figure 3.2D). The IRS1 protein tyrosine phosphatase 
activity of PTEN could also be detected using the pY989-specific IRS1 antibody and a 
general phospho-tyrosine antibody. Importantly, in these experiments, we found that 
the protein phosphatase activity of PTEN was specific for phospho-IRS1 and that 
phosphorylation status of IGF1R (both Y1135/1136 and Y980 sites) was not affected 
by PTEN (Figure 3.2C, D). 
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                To further disentangle the lipid and protein phosphatase activities of PTEN, 
we also generated recombinant protein (Figure 3.3) with a recently reported PTEN 
mutation, Y138L(YL), possessing lipid but not protein phosphatase activity (Davidson 
et al., 2010). Indeed, the YL mutant could not dephosphorylate IRS1 in vitro (Figure 
3.3). However, unlike the GE or CS mutants, the YL mutant did possess lipid 
phosphatase activity, but this activity was considerably lower than that of WT PTEN 
(Figure 3.3).  
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Figure 3.1 
 
WT PTEN but not the CS or GE mutant has lipid phosphatase activity. (A) 
Validation of PTEN shRNA MEFs reconstituted with GFP-S-tagged PTEN 
(WT/CS/GE). (B) WT PTEN but not the CS or GE mutant can inhibit EGF-induced 
AKT activation. GFP-S-tagged PTEN (WT/CS/GE) was overexpressed in MEFs with 
stable PTEN shRNA. Cells were serum starved for 3 hrs and then treated with 100 
ng/ml EGF for 5 min. (C) WT PTEN but not the CS or GE mutant PTEN can inhibit 
EGF-induced cellular PIP3 generation. GFP-S-tagged PTEN (WT/CS/GE) was 
overexpressed in PTEN negative PC3 cells. Cells were serum starved for 6 hrs and 
then treated with 100 ng/ml EGF for 5 min. Cellular PIP3 concentration was measured 
as described in methods. 
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Figure 3.2  
 
PTEN is a protein phosphatase for IRS1 in vitro. (A) Coomassie blue gel showing 
purified recombinant PTEN proteins. WT: wild-type; CS: C124S mutant; GE: G129E 
mutant. (B) WT PTEN but not the CS or GE mutant dephosphorylates PIP3. The assay 
was performed as described in Methods. 40 μM PIP3 and 0.1 μM PTEN (WT), 10 μM 
PTEN (CS) and 10 μM PTEN (GE) proteins were used in the assay. (C) WT-PTEN 
dephosphorylates IRS1 but not IGF1R. HA-IRS1 and HA-IGF1R were co-expressed 
in 293 cells, and cells were treated with IGF1 to trigger their phosphorylation. IRS1 
and IGF1R were immunoprecipitated from cell lysates by HA-antibody, and were 
subsequently incubated with recombinant PTEN (WT) protein (0.3 or 0.6 µM, as 
indicated) with or without phosphatase inhibitor cocktail (Y inhibitor) for 1 hr at 30
o
C. 
(D) GE but not CS mutant PTEN can dephosphorylate IRS1 but not IGF1R. 
Immunoprecipitated IRS1 and IGF1R were incubated with recombinant PTEN (GE or 
CS mutant) protein (0.3 or 0.6 µM) with or without phosphatase inhibitor cocktail (Y 
inhibitor) for 1 hr at 30
o
C. 
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Figure 3.3  
 
Characterization of recombinant PTEN protein in lipid and protein phosphatase 
assays. (A) Coomassie blue gel showing purified recombinant PTEN proteins. WT: 
wild-type; YL: Y138L mutant; CS: C124S mutant; GE: G129E mutant. (B) WT-
PTEN or GE but not YL or CS mutant can dephosphorylate IRS1. Immunoprecipitated 
IRS1 was incubated with recombinant PTEN (WT, YL GE or CS mutant) protein (0.6 
µM) for 1 hr at 30
o
C. (C) Comparing PTEN (WT or mutants) activity in a lipid 
phosphatase assay. The assay was performed similar to that in Figure 3.2B, with 40 
µM PIP3 and PTEN (WT/YL/CS/GE) proteins of indicated concentrations. 
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PTEN is a protein tyrosine phosphatase for IRS1 in cells 
 
              Given the data that purified PTEN was an IRS1 phosphatase, we sought to 
determine whether it also functioned as a NEDD4-suppressed IRS1 phosphatase in 
cells. In cellular reconstitution experiments, we blocked IGF1 induction of IRS1 
phosphorylation with Dox-inducible NEDD4 RNAi, and restored IRS1 
phosphorylation by knocking down PTEN expression (Figure 3.4A). After induction 
of NEDD4 RNAi with Dox, IGF1-induced phosphorylation of IRS1 and AKT was 
greatly reduced in the PTEN-RNAi cells in which wild-type PTEN was re-expressed 
(Figure 3.4B), but not reduced in the PTEN-RNAi cells in which CS mutant PTEN 
was re-expressed (Figure 3.4C). Similar to wild-type PTEN, after induction of 
NEDD4 RNAi with Dox, IGF1-induced phosphorylation of IRS1 and AKT was 
greatly reduced in the PTEN-RNAi cells in which GE mutant PTEN was re-expressed 
(Figure 3.4D). Effects of wild-type PTEN or PTEN mutants on NEDD4-mediated 
IRS1 phosphorylation were also quantified in Figure 3.4E, demonstrating the 
reproducibility of the experiments. 
             These data demonstrate that PTEN acts as an IRS1 phosphatase in cells and 
that this activity is dependent on the protein phosphatase activity but not PIP3 
phosphatase activity of the enzyme. In these cells, the effect of PTEN on IGF-induced 
IRS1 phosphorylation could be detected by using antibodies specific to both pY608 
site and pY989 site of IRS1 (Figure 3.5), which was consistent with our in vitro 
observations. 
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            The result that the PIP3 phosphatase-defective GE mutant could also reduce 
IRS1 phosphorylation, like WT PTEN, indicated that the effect of PTEN on IRS1 
phosphorylation was not likely through indirect feedback regulation caused by the 
change of downstream PIP3 level or AKT activity. To further rule out the possible 
feedback mechanisms caused by PIP3/AKT changes, we performed similar 
experiments in the presence of a pharmacological inhibitor of PI3K (GDC0941). This 
inhibitor prevented IGF1-induced PIP3 generation, as demonstrated by the lack of 
downstream AKT activation, although the upstream phosphorylation of IGF1R or 
IRS1 remained intact (Figure 3.6A). In the presence of the inhibitor, Dox-induced 
NEDD4 RNAi ablated IGF1-induced IRS1 phosphorylation in PTEN-knockdown 
cells only when PTEN was re-expressed in the cells (Figure 3.6B). While in the 
absence of PTEN expression, and in the presence of the PI3K inhibitor, Dox-induced 
NEDD4 RNAi could not ablate IGF1-induced IRS1 phosphorylation (Figure 3.6C).  
             To demonstrate the specificity of the regulation of NEDD4-PTEN on IGF 
signaling, we did similar experiments with serum or EGF treatment (Figure 3.7). 
Generally, serum-induced AKT activation was not affected, while NEDD4 
knockdown led to elevated EGFR phosphorylation, but little change in p-AKT level 
upon EGF treatment. 
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Figure 3.4 
 
PTEN is a protein phosphatase for IRS1 in cells. (A) When PTEN expression is 
knocked down, IGF1 can induce IRS1 phosphorylation in the absence of NEDD4. 
MEFs harboring inducible NEDD4 shRNA (with or without Dox treatment as 
indicated) were subjected to transient PTEN knockdown and followed by serum-
starvation and then 50 ng/ml IGF1 stimulation. (B) Re-expressing wild-type PTEN 
blocked IGF1-induced IRS1 phosphorylation in NEDD4-RNAi/PTEN-RNAi MEFs. 
MEFs as in panel A were reconstituted with shRNA-resistant GFP-S-PTEN (WT) by 
transient retroviral infection and subjected to the same treatment as in panel A. (C) Re-
expressing the CS mutant of PTEN cannot block IGF1-induced IRS1 phosphorylation 
in NEDD4-RNAi/PTEN-RNAi MEFs. (D) Re-expressing the GE mutant of PTEN can 
block IGF1-induced IRS1 phosphorylation in NEDD4-RNAi/PTEN-RNAi MEFs. (E) 
Quantification of the effect of PTEN (WT or indicated mutants, as in Panel a-d) on 
NEDD4-mediated IRS 1phosphorylation. Each pIRS1 signal on western blots was 
quantitated by densitometer and normalized by total IRS1 signal. The ratio of pIRS1 
(+ DOX, thus in the absence of NEDD4 expression) versus pIRS1 (- DOX) was 
plotted for specific conditions as indicated. Error bars show s.e.m. from four 
independent experiments. 
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Figure 3.5  
 
WT and GE mutant, but not CS mutant, PTEN can dephosphorylate the 
phospho-tyrosine 989 site of IRS1 in cells. The experiments were performed the 
same as that in Figure 3.4 except that both p-IRS1 (Y608) and p-IRS1 (Y989) were 
assessed here. 
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Figure 3.6  
 
PI3K inhibitor does not affect the PTEN function as IRS1 protein phosphatase. 
(A) PI3K inhibitors block IGF1-induced phosphorylation of AKT but not that of 
IGF1R or IRS1. WT MEFs were pretreated for 1 hr with either 2 µM BYL-719 or 1 
µM GDC0941, followed by 50 ng/ml IGF1 for 10 min. (B) PI3K inhibitor (GDC0941) 
does not affect the function of wild-type PTEN on IGF1-induced IRS1 
phosphorylation in NEDD4-RNAi/PTEN-RNAi MEFs. (C) PI3K inhibitor (GDC0941) 
has no effect on IGF1-induced IRS1 phosphorylation in NEDD4-RNAi/PTEN-RNAi 
MEFs. 
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Figure 3.7  
 
NEDD4 RNAi has no inhibitory effect on EGF signaling. (A) Re-expressing wild-
type PTEN does not block EGF signaling in NEDD4-RNAi/PTEN-RNAi MEFs. (B) 
Re-expressing the CS or GE mutant of PTEN cannot block EGF signaling in NEDD4-
RNAi/PTEN-RNAi MEFs. 
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                  It should be noted that, in these cellular experiments, we used transient 
PTEN knockdown because, as we and other have previously demonstrated, permanent 
PTEN loss causes a marked decrease in IGF1R expression and thus deficiency of IGF 
signaling, and AKT inhibition increases IGF1R expression by relieving feedback 
inhibition of FOXO (Chandarlapaty et al., 2011; Qin et al., 2011). As shown in Figure 
3.8, both genetic deletion of PTEN gene and long-term, stable PTEN shRNA caused a 
decline in IGF1R levels. Indeed, treating PTEN
-/-
 MEFs or PTEN-shRNA MEFs with 
an AKT inhibitor enhanced IGF1R expression (Figure 3.8A, B). Re-expressing wild-
type but not CS or GE mutant PTEN could also restore IGF1R expression in PTEN
-/-
 
MEFs but had no effect on EGFR levels (Figure 3.8C). Nevertheless, AKT inhibition 
by AKTi increased IGF1R to similar level in all the cell lines. Consistent with such 
feedback regulation, stable knockdown of PTEN only minimally enhanced IRS1 
phosphorylation in NEDD4
-/-
 MEFs, although it substantially restored IGF1-induced 
AKT activation, presumably by suppressing the PIP3 phosphatase activity of PTEN 
(Figure 3.8D). 
                To better understand the mechanism of how PTEN regulates IRS1, we 
mapped domains for the interaction between PTEN and IRS1. PTEN contains multiple 
domains, including an N-terminal phosphatase domain, a central C2 domain and a C-
terminal tail. The C-terminal tail is a long flexible fragment that is mainly involved in 
PTEN regulation (Lee et al., 1999). So we generated a series of PTEN truncation 
fragments and tested their interaction with IRS1, indicating C2 domain is necessary 
and sufficient for interaction (Figure 3.9A). IRS1 has both PH domain and PTB 
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domains near the N terminus. The central and C terminus of the IRS proteins contain 
up to 20 potential tyrosine-phosphorylation sites that, after phosphorylation by the IR, 
bind to intracellular molecules that contain SH2 domains (Copps and White, 2012). 
Preliminary truncation studies revealed that the N-terminal of IRS1 was required for 
binding to PTEN (Figure 3.9B). 
              Taken together, these results reveal the novel function of PTEN as a protein 
phosphatase for IRS1, as well as mechanisms underlying specific regulation of IGF 
signaling by PTEN and NEDD4 (see Figure 3.10 for a model). It has been a long-
standing debate concerning whether PTEN is a biologically relevant protein 
phosphatase. Thus, our demonstration of the biochemical nature of PTEN as both a 
protein and lipid phosphatase is significant. Additionally, until now, the biochemical 
effects of PTEN in PI3K signaling have been completely ascribed to its lipid 
phosphatase activity. Through this work, we have now obtained evidence showing that 
PTEN is a protein phosphatase and can down-regulate PI3K signaling in a least two 
ways: generally by decreasing PIP3 levels, and in a manner specific to IGF/insulin 
signaling, by dephosphorylating IRS1.  
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Figure 3.8  
 
PTEN and AKT regulate IGF1R expression via feedback mechanism. (A) PTEN
-/-
 
MEFs express lower levels of IGF1R which can be increased by AKT inhibition. WT 
or PTEN
-/-
 MEFs were treated with 1 µM AKTi for 12 or 24 hrs. (B) MEFs harboring 
long-term PTEN shRNA have decreased IGF1R expression, which can be reversed by 
AKT inhibition. (C) Expression of wild-type but not CS or GE mutant PTEN 
increased IGF1R expression in PTEN
-/-
 MEFs. PTEN
-/-
 MEFs were reconstituted with 
GFP or GFP-S-PTEN (WT/CS/GE), and treated with or without 1 µM AKTi for 24 
hrs. (D) Stable PTEN shRNA restored IGF1-induced AKT activation in NEDD4
-/-
 
MEFs but had minimal effect on IRS1 phosphorylation. NEDD4
-/-
 MEFs with control 
knockdown or stable PTEN knockdown were serum-starved, and then stimulated with 
50 ng/ml IGF1 for 5 min, with or without 1 µM PI3K inhibitor.  
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Figure 3.9 
 
Domain mapping for interaction between PTEN and IRS1. (A) Schematic of 
PTEN fragments. 293T cells were transfected with S-tagged IRS1 and indicated PTEN 
fragments. Cell lysates were immunoprecipitated by S-protein agarose and followed 
by immunoblotting for PTEN and IRS1. (B) Schematic of IRS1 fragments. 293T cells 
were transfected with S-tagged PTEN and indicated IRS1 fragments. Cell lysates were 
immunoprecipitated by S-protein agarose followed by immunoblotting for PTEN and 
IRS1. 
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Figure 3.10 
  
Model showing that IGF but not EGF signaling pathway is regulated by the 
NEDD4-PTEN circuitry. Upon IGF and insulin signaling, the IRS1 protein 
phosphatase activity of PTEN is antagonized by NEDD4. This mechanism accounts 
for the specific requirement of NEDD4 in IGF signaling but not EGF signaling. The 
lipid phosphatase activity of PTEN down-regulates both IGF and EGF signals. 
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DISCUSSION 
 
              This study establishes that PTEN is a protein tyrosine phosphatase for IRS1, 
which is under specific regulation by NEDD4. Therefore, PTEN has dual functions for 
IGF or insulin signaling, as a lipid phosphatase for PIP3 and as a protein tyrosine 
phosphatase for IRS1. PTEN’s function as an IRS1 tyrosine phosphatase is usually 
masked by the negative feedback regulation of the PI3K-AKT pathway 
(Chandarlapaty et al., 2011; Qin et al., 2011). Generally, manipulation of PTEN 
protein levels lead to immediate change in AKT phosphorylation, thus the expression 
and phosphorylation of multiple RTKs. In addition, IRS1 is negatively regulated by 
serine phosphorylation due to mTORC1-S6K1 signaling (Copps and White, 2012; 
Harrington et al., 2004; Ozes et al., 2001), which is also activated by AKT. That’s why 
stable PTEN knockdown or knockout often led to a decrease in IRS1 tyrosine 
phosphorylation, while over-expression of WT PTEN increased tyrosine 
phosphorylated IRS1 (unpublished data). Luckily, the novel function of PTEN was 
revealed when NEDD4 is absent upon IGF or insulin stimulation. It seems that the 
ubiquitin E3 ligase constitutively suppresses protein phosphatase activity of PTEN 
towards IRS1. 
               So far, six of family members of IRS proteins have been identified and 
termed IRS1-6.  IRS1 and IRS2 are widely distributed, whereas IRS3, 4, 5, 6 had 
limited expression (Taniguchi et al., 2006). IRS1 and IRS2 contain highly similar N-
terminal PH and PTB domains, followed by long unstructured C-terminal tail regions. 
For the conserved N-terminal region which is responsible for interaction between 
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IRS1 and PTEN, IRS1 and IRS2 only share 49% identical sequences. Furthermore, 
IRS2 contains fewer YXXM motifs than IRS1 that could be tyrosine phosphorylated 
and mediate binding to PI3K. Our preliminary data showed that IRS2 is probably not a 
protein substrate for PTEN (unpublished data).  
             In addition to PTEN, other protein phosphatases could also negatively regulate 
IGF/insulin signaling. For example, TCPTP and PTP1B can inactivate insulin 
signaling by dephosphorylating the insulin receptor, and PTP1B may also 
dephosphorylate IRS1 (Galic et al., 2005; Goldstein et al., 2000; Tiganis, 2013). How 
does the IRS1 phosphatase activity of PTEN coordinate with these additional 
regulatory mechanisms, and do these protein phosphatases function differentially, e.g., 
in a tissue and/or context-specific manner? Understanding these questions will provide 
further insights into the mechanisms and biology of IGF/insulin signaling. 
              Noticeably, NEDD4 RNAi resulted in increased EGF signaling, especially 
elevated EGFR phosphorylation. This could be explained by the indirect effect of 
NEDD4 on EGFR protein level, through ubiquitinating ACK (activated Cdc42-
associated tyrosine kinase) which is involved in EGF-induced degradation of EGFR 
(Lin et al., 2010). This might also contribute to the special requirement of NEDD4 for 
IGF/insulin signaling.  
              This work also raises many important questions for future study. It is likely 
that the intensity and duration of IGF signaling in different tissues could be achieved 
by tuning the expression and activity of the PTEN and NEDD4 enzymes. It can also 
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be speculated that NEDD4 may be specifically stimulated by IGF/insulin signaling but 
not other RTKs to neutralize the inhibitory activity of PTEN. Furthermore, we 
speculate that the regulation of IGF/insulin signaling by PTEN and NEDD4 could play 
key roles in the pathophysiology of cancers (such as Ewing’s sarcoma) and metabolic 
diseases (such as diabetes and obesity). Beyond IGF signaling, our findings warrant a 
systematic search and functional investigation of other cellular phosphoproteins that 
might be subject to regulation by the protein phosphatase activity of PTEN. 
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CHAPTER FOUR 
CHARACTERIZATION OF A NEW FORM OF PTEN 
 
INTRODUCTION 
 
               The  classic “Kozak sequence” CCACCATGG, has been shown to the most 
favorable sequence context for translation initiation (Kozak, 1991). In certain 
transcripts, translation initiation could occur from non-AUG codons. Kozak found that 
GUG and CUG were both capable of initiating translation in vitro far less efficiently 
(Kozak, 1989). The transcription factor, c-myc, has an alternate upstream CUG 
initiation codon, which adds 14 amino acids to the N-terminus of the protein (Hann et 
al., 1988). Actual subcellular localization of a protein can be dictated by alternate 
initiation codons. For example, human FGF3, if translation is initiated from AUG it 
enters the secretory pathway while protein translated from an upstream CUG localizes 
to the nucleus (Kiefer et al., 1994). 
                 In addition to 403-amino acid PTEN, a 576-amino acid translational variant 
of PTEN was identified, which was generated from an alternative translation start site 
(Hopkins et al., 2013). The same group also showed that this longer version of PTEN 
could be secreted from cells and entered other cells. A very recent paper reported that 
translation of the same upper band was initiated from a CUG codon upstream and 
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Eukaryotic translation initiation factor 2A (eIF2A) controls its translation (Liang et al., 
2014). Furthermore, they found that the protein induced cytochrome c oxidase activity 
and ATP production in mitochondria.  
                   Intriguingly, two groups identified the same PTEN protein species as 
PTEN by SUMOylation (SUMO, small ubiquitin-like modifier). One group showed 
that PTEN was covalently modified by SUMO1 at both K266 and K254 sites in the 
C2 domain (Huang et al., 2012). The other group mapped the SUMOylation site at 
position 254, which controls PTEN nuclear localization (Bassi et al., 2013).   
 
RESULTS 
Identify of UPP 
                During immunoblotting for endogenous PTEN in cell lysates, we noticed an 
upper protein band of PTEN (termed UPP) of molecular mass ~75-kD (Figure 4.1A). 
This upper band could be detected by with two PTEN-specific antibodies in various 
mammalian cells, including human breast (MCF7), WT MEFs, human 293 and human 
osteosarcoma (U2OS) cells. While UPP cannot be detected in known PTEN-negative 
cells including breast cancer (MDA-MB-468) and prostate cancer (PC3) cells. We also 
tested more mammalian cells (Figure 4.1B) and UPP coexisted with PTEN in all 
PTEN positive cells such as epidermoid carcinoma (A431), monkey Cos-1, mouse 
NIH3T3, and colorectal carcinoma (HCT116). As expected, UPP was absent from 
cells lacking PTEN (prostate cancer (LNCaP, PC3) and PTEN
-/-
 MEFs). 
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             To study the connection between PTEN and UPP, we engineered MEFs to 
express two different Dox-inducible shRNA against PTEN (Figure 4.2A). When 
PTEN RNAi was induced for 24 hours, PTEN protein level barely changed while UPP 
was substantially depleted. Nevertheless, 48 hours PTEN RNAi resulted in notable 
reduction of both PTEN and UPP, supporting that UPP and PTEN were correlated on 
mRNA level. To test if exogenous PTEN could induce UPP generation (Figure 4.2B), 
PTEN cDNA with different tags were transfected into 293T cells, then immunoblotted 
with PTEN antibody. However, none could give rise to the UPP band, contradicting 
the notion that UPP was a posttranslational modification of PTEN.  
             To identify the UPP band, we attempted to separate endogenous UPP from 
PTEN in HeLa cell extracts, using ammonium sulfate precipitation, a series of 
chromatography and final immune-precipitation with PTEN antibody (Figure 4.3A). 
The eluate from last step of purification was silver stained and sent for mass 
spectrometry (Figure 4.3B).  When the sequencing result was compared with the 
NCBI database from before June 2013, it was only identified as PTEN. 
                In 2013, a group published the identity of PTEN upper band in science 
(Hopkins et al., 2013). They named it PTEN-Long, as 576-amino acid translational 
variant of PTEN. When we compared the mass spectrometry result for UPP with that 
of PTEN-Long, there was a complete match (Figure 4.4A). UPP shares the same 
identity as PTEN-long, translated from upstream CTG as diagrammed in Figure 4.4B. 
Then we generated UPP mutants for distinctive expression patterns (Figure 4.4C). 
UPP-CTG expressed as a major PTEN band and a minor UPP band. When the original 
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CTG was mutated into ATG, the ratio of UPP vs PTEN is about 1:1. While the 
original ATG was mutated into ATA, only UPP band could be detected. We used 
UPP(ATG/ATA) for our following studies of UPP. 
 
Figure 4.1  
 
Immunoblot of whole-cell lysates of cell lines of known PTEN status. (A) Western 
blots of whole-cell lysates of MDA-MB-468, MCF7, WT MEFs, 293, U2OS and PC3. 
MDA-MB-468 and PC3 are PTEN negative. (B) Western blots of whole-cell lysates of 
A431, Cos-1, LNCaP, NIH3T3, PC3, 293, U2OS, HCT116, WT MEFs and PTEN
-/-
 
MEFs. LNCaP, PC3 and PTEN
-/-
 MEFs are PTEN negative. 
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Figure 4.2  
 
Correlation between UPP and endogenous PTEN. (A) UPP decreases when PTEN 
is knocked down by RNAi. WT MEFs haring Dox-inducible PTEN shRNA constructs 
(shPTEN-A, shPTEN-B) were treated with Doxycycline with indicated concentration 
and time. (B) Expression of exogenous PTEN fails to generate UPP. 293T cells were 
transfected with indicated plasmids and UPP (ATG)-HA as positive control.  
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Figure 4.3  
 
Purification of endogenous UPP. (A) Endogenous UPP purification strategies. 
Starting material is supernatant of HeLa nuclei extracted with 1% Triton. After 
ammonium sulfate precipitation, UPP is completely separated from PTEN by 
chromatography. Endogenous UPP is enriched by immunoprecipitation by PTEN 
antibody. (B) Immunoblot of UPP from purification steps. (Data were generated by 
Wei Pan in Dr.Jiang’s lab) 
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Figure 4.4 
 
Identity of UPP. (A) Mass spec data and comparison with known PTEN-long 
sequence. Matched sequence is highlighted in red.  (B) PTEN and UPP domain 
structures. Normal PTEN translation starts at ATG, while UPP is translated from 
upstream CTG codon. (C) Schematics of UPP mutants and expression in 293T cells.  
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Subcellular localization of UPP            
               Since UPP contains over 150 additional amino acids at its N-terminus, we 
wanted to study if they altered the biochemical properties of the protein. To study the 
stability and subcellular localization of UPP, we treated WT MEFs with 
cycloheximide, an inhibitor of protein synthesis, and fractionated cell lysate using 
hypotonic buffer and ultracentrifugation (Figure 4.5A).  The majority of endogenous 
PTEN was in the cytosol soluble fraction, while most of UPP was in the pellet. When 
protein synthesis was blocked, UPP levels decreased dramatically, while PTEN 
remained quite stable, suggesting UPP had a shorter half-life than PTEN. Similarly, 
when MG132, a proteasome inhibitor, was used to block degradation of ubiquitin-
conjugated proteins, only UPP accumulated in the pellet fraction, supporting that UPP 
is the fast turnover subpopulation of PTEN (Figure 4.5B).  
                Our fractionation data showed that UPP has a distinct subcellular 
localization from PTEN. To verify this, we engineered MCF7 cells expressing Dox-
inducible expression of C-terminal GFP-tagged PTEN or UPP. As shown in Figure 
4.5C, PTEN-GFP was present in both cytosol and nucleus, but UPP-GFP was 
excluded from nucleus and exhibited a unique pattern from PTEN.   
                 For a better understanding of the subcellular localization of UPP, we 
recorded the Dox-inducible expression of UPP-GFP or PTEN-GFP using time-lapse 
microscopy. Still images from different time points showed that UPP-GFP was 
synthesized in cytoplasm, stayed outside the nucleus and transient translocations to the 
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plasma membrane and cell-cell junctions (Figure 4.6B). In contrast, PTEN-GFP was 
synthesized in cytoplasm, but trans-located to the nucleus and demonstrated less 
frequent localization to plasma membrane (Figure 4.6A). 
              To pinpoint the localization of UPP on the membrane networks of cells, we 
checked different organelle markers for potential co-localization. As reported recently 
(Liang et al., 2014), UPP was detected predominantly in the cytoplasm and 
mitochondria. We tested if UPP co-localized with mitochondria using MitoTracker in 
live cells (Figure 4.7A) and immunofluorescence by cytochrome C antibody (Figure 
4.7B). However, we did not observe the subcellular localization of UPP or PTEN on 
mitochondria.  
                 Next we tested a series of antibodies for organelle markers (Figure 4.8). As 
a maker for endoplasmic reticulum (ER),  carboxyl-terminal tetrapeptide KDEL signal 
is essential for retention of resident proteins in the lumen of ER (Pelham, 1990). 
Nevertheless, immunofluorescence with KDEL antibody showed little co-localization 
with UPP-GFP (Figure 4.8A).   Then we tested several early endosome markers, 
including Rab5 (Figure 4.8B) and EEA1 (Figure 4.8C). Rab5 is a key regulator of 
early endocytosis and localizes at the plasma membrane and early endosomes (Zerial 
and McBride, 2001), while EEA1 is a Rab5 effector required for early endosomal 
membrane fusion and trafficking (Christoforidis et al., 1999). Interestingly, there was 
partial co-localization of UPP-GFP with both Rab5 and EEA1. Furthermore, Syntaxin 
6, a member of SNARE protein which is localized to the trans-Golgi network and 
within endosomes (Wendler and Tooze, 2001), showed partial co-localization with 
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UPP-GFP as well (Figure 4.8D). Taken together, UPP-GFP appears to be involved in 
the endocytic pathway involving membrane trafficking.  
                  From live imaging of Dox-inducible expression of UPP-GFP, we noticed 
the transient localization of UPP-GFP on ruffled plasma membranes and areas of cell-
cell adhesion (Figure 4.6B). Therefore, we tested if UPP-GFP was localized on 
adherens junctions, employing E-caderin (Figure 4.9A) and β-catenin antibody as 
markers (Figure 4.9B). As a member of transmembrane glycoproteins which mediated 
calcium-dependent cell-cell adhesion (Wheelock and Johnson, 2003), E-caherin 
staining showed substantial co-localization with UPP-GFP. Additionally, we also 
detected clear co-localization of UPP-GFP and β-catenin, which binds to the 
cytoplasmic tail of E-cadherin at adherens junctions (Xu and Kimelman, 2007). These 
data supported the localization of UPP on adherens junctions.  
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Figure 4.5 
 
UPP is the fast turnover subpopulation with distinctive subcellular localization. 
(A) Cycloheximide treatment and fractionation. WT MEFs were treated with 10μg/ml 
cycloheximide for indicated time, and then subjected to fractionation using hypotonic 
buffer and ultracentrifuge. (B) MG132 treatment and fractionation. WT MEFs were 
treated with 25μM MG132 for indicated time and subjected to fractionation. (C) UPP 
shows a different subcellular localization from PTEN. MCF7 cells were transduced 
with lentivirus expressing PTEN-GFP or UPP-GFP.   
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Figure 4.6 
 
Live cell imaging: Dox-inducible expression of PTEN-GFP or UPP-GFP in MCF7. 
MCF7 cells were transduced with lentivirus expressing PTEN-GFP (A) or UPP-GFP 
(B).  After changing to fresh medium with 1µg/ml Dox, cells were subjected to live 
cell imaging.        
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Figure 4.7  
 
UPP does not localize on mitochondria. (A) MCF7 cells expressing UPP-GFP or 
PTEN-GFP were treated with 10µM MitoTracker for 20min then subjected to confocal 
fluorescence microscopy. (B)  MCF7 cells expressing UPP-GFP were subjected to 
immunofluorescence by cytochrome C antibody.  
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Figure 4.8 
 
UPP is localized on endosomes. MCF7 cells expressing UPP-GFP were subjected to 
immunofluorescence by antibodies (A) KDEL, (B) Rab5, (C) EEA1 and (D) Syntaxin 
6. 
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Figure 4.9 
 
UPP co-localizes with E-cadherin/β-catenin. MCF7 cells expressing UPP-GFP were 
subjected to immunofluorescence by antibodies (A) E-cadherin and (B) β-catenin.  
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                Interestingly, when WT MEFs were treated with 1% oxygen hypoxia for a 
few hours, we noticed a slight decrease in the UPP band, but not PTEN, which 
correlated with an increase in p-AKT(S473) (Figure 4.10A). When cells were 
subjected to fractionation, the down-regulation of UPP is obvious in the membrane 
fraction (Figure 4.10B). 
 
 
Figure 4.10  
 
UPP regulation during hypoxia. (A) Hypoxia treatment on WT MEFs. WT MEFs 
were treated with 1% oxygen hypoxia for indicated time and whole cell lysate were 
analyzed. (B) Hypoxia treatment and fractionation. WT MEFs were treated with 1% 
oxygen hypoxia for indicated time and subject to fractionation.  
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UPP is an active lipid phosphatase  
              Since UPP is a translational variant of PTEN, we tested if additional amino 
acids regulated its enzymatic activity. Analysis of the extra peptide using SignalIP3.0 
predicted a signal peptide which might be cleaved at amino acid 22 (Figure 4.11A). To 
compare the enzymatic activities of PTEN and UPP, recombinant C-terminal his-
tagged PTEN, UPP or UPP without signal peptide (UPP (-) S) protein were generated 
in SF9 cells. Then their enzymatic activities were measured against the lipid substrate 
PtdIns(3,4,5)P3. UPP demonstrated comparable lipid phosphatase activity 
dephosphorylating diC8PIP3 , either in phospholipid vesicles (PLV) (Figure 4.11B) or 
water (Figure 4.11C).  
                 Then lipid phosphatase activities of PTEN and UPP were compared in 
PTEN-negative cells. PTEN
-/-
 MEFs were transduced with retrovirus expressing either 
PTEN or UPP. Even though the level of exogenous UPP was much lower than 
exogenous PTEN, they had comparable inhibition on basal AKT phosphorylation 
(Figure 4.12A). We also transiently over-expressed PTEN or UPP in various PTEN-
negative cancer cell lines, including PC3, MDA-MB-468 and T89G. UPP, expressed 
at much lower levels, demonstrated similar inhibition of basal p-AKT, in comparison 
with PTEN (Figure 4.12B). Then we measured lipid phosphatase activities of PTEN 
and UPP on insulin-stimulated AKT phosphorylation in cells through imaging. MCF7 
cells transiently expressing either PTEN-GFP or UPP-GFP were serum starved, then 
stimulated with insulin.  Immunofluorescence of endogenous p-AKT (S473) showed 
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that UPP-GFP blocked insulin-induced AKT phosphorylation similarly as PTEN-GFP 
(Figure 4.12C and D). 
               For better control of the expression levels of the proteins, we engineered PC3 
cells with Dox-inducible over-expression of PTEN or UPP and picked stable clones. 
24 hour of Dox treatment induced comparable levels of expression of PTEN or UPP, 
with similar suppression of p-AKT (T308/S473) (Figure 4.13A). Next we tested the 
growth potential of the stable clones in colony formation assay. Dox-inducible UPP 
over-expression led to slightly better inhibition on colony numbers, however, UPP 
was expressed at slightly higher levels (Figure 4.13B). 
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Figure 4.11  
Comparison of lipid phosphatase activity of PTEN and UPP in vitro. (A) 
Sequence analysis of UPP-specific sequence. (B) Lipid phosphatase assays were 
performed with indicated recombinant protein with 40 M diC8PIP3 and 0.5mM 
DOPS. (C) Lipid phosphatase assays were performed with indicated recombinant 
protein with 40 M diC8PIP3. 
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Figure 4.12 
 
Lipid phosphatase activity of UPP in cells. (A) Transient o/e of PTEN or UPP in 
PTEN
-/-
 MEFs. PTEN-/- MEFs were transduced with retrovirus expressing PTEN or 
UPP. 48 hours later, cells were harvested and subjected to western blot. (B) Transient 
o/e of PTEN or UPP in PTEN negative cancer cells. PC3, MDA-MB-468 and T89G 
were transduced with retrovirus expressing PTEN or UPP. 48 hours later, cells were 
harvested and subjected to western blot. (C) Immunofluorescence of Dox-inducible 
o/e of PTEN in MCF7 cells upon insulin treatment. MCF7 cells expressing PTEN-
GFP were serum starved, then treated with 1μg/ml insulin for 10 min. p-AKT (S374) 
antibody was used for immunofluorescence.  (D) Immunofluorescence of Dox-
inducible o/e of UPP in MCF7 cells upon insulin treatment. MCF7 cells expressing 
UPP-GFP were serum starved, then treated with 1μg/ml insulin for 10 min. p-AKT 
(S374) antibody was used for immunofluorescence.   
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Figure 4.13 
 
Growth Suppression activity of UPP in PC3 cells. (A) Dox-inducible o/e of PTEN 
or UPP in PC3 cells. Stable clones of PC3 harboring Dox-inducible PTEN or UPP 
expression were treated with or without 1μg/ml Dox for 24 hours. (B) Dox-inducible 
o/e of PTEN or UPP in colony formation assay. 1X10
3
 cells of stable clones of PC3 
harboring Dox-inducible PTEN or UPP expression were seeded in 6-well plates, and 
then treated with or without 1μg/ml Dox for 10 days. 
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UPP is a better binding partner for IRS1          
              As discussed in chapter two, PTEN is a binding partner and protein tyrosine 
phosphatase for IRS1. Naturally, we measured the capacity of UPP to bind to IRS1. 
When S-tagged PTEN or UPP were IPed from cells expressing HA-tagged IRS1, 
much more IRS1 were in the complex with UPP than with PTEN, independent of the 
predicted signal peptide on N-terminus of UPP (Figure 4.14A).  
              To confirm the Co-IP data, we IPed S-tagged IRS1 from cells expressing 
equal amounts of exogenous PTEN or UPP, using UPP (ATG/ATG) mutant.  
Consistently, IRS1 bound with UPP preferentially, and the interaction could also be 
blocked by overexpressing wild-type NEDD4, but not enzymatically dead NEDD4 
(Figure 4.14B). To rule out the possibility that the longer UPP protein randomly stuck 
to beads or proteins, S-tagged IGF1R were pulled down from cells expressing equal 
amounts of PTEN or UPP. In contrast with IRS1, IGF1R bound equally to both PTEN 
and UPP (Figure 4.14C).  
              One dilemma about the importance of endogenous UPP is that its protein 
level is much lower than that of endogenous PTEN in cells. To address the biological 
function of UPP, we generated UPP-knockout or PTEN-knockout MCF7 cells, using 
CRISPR/Cas9 technology. Among the four PTEN knockout stable clones, complete 
PTEN loss (stable clones #1 and #2) led to dramatic increase in p-AKT (T308), but 
little change in IRS1 tyrosine phosphorylation, probably due to negative feedback 
regulation (Figure 4.15). While partial PTEN loss (stable clone #3) and complete UPP 
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depletion (stable clones UPP #1,2,3,4) resulted in slight up-regulation of pAKT (T308) 
and substantial increase of IRS1 tyrosine phosphorylation, suggesting UPP might be a 
physiological tyrosine phosphatase for IRS1 in MCF7.  
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Figure 4.14  
 
UPP is better binding partner to IRS1, but not IGF1R. (A) Compared with PTEN, 
UPP is a better binding partner for IRS1. 293T cells were transfected with IRS1-HA 
and indicated GFP-S-tagged constructs. PTEN or UPP were pulldown by S-protein 
agarose. Interaction with IRS1 were detected by HA antibody. (B) IRS1 binds 
preferentially to UPP. 293T cells were transfected with S-tagged IRS1 and C-terminal 
HA-tagged UPP (ATG) mutant expressing equal amount of PTEN and UPP. IRS1 
were pulldown by S-protein agarose. (C) IGF1R binds equally to PTEN or UPP. 293T 
cells were transfected with S-tagged IGF1R and C-terminal HA-tagged UPP (ATG) 
mutant expressing equal amount of PTEN and UPP. IGF1R was pulldown by S-
protein agarose. 
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Figure 4.15  
UPP-KO leads to more basal IRS1 tyrosine phosphorylation, but not AKT 
phosphorylation. Single clones of either PTEN or UPP knockout were generated by 
CRISPR/Cas9.  
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DISCUSSION 
 
               In this study, we purified the endogenous upper protein band of PTEN and 
the mass spectrometry result confirmed that it was indeed alternative translation of 
PTEN from the alternative CTG start codon. Surprisingly, exogenous over-expression 
of different-tagged versions using PTEN cDNA failed to generate the upper protein 
band, suggesting UPP is not a post-translational modification of PTEN. Subcellular 
fractionation and imaging data revealed a distinctive localization and shorter half-life 
of UPP compared to PTEN. Using biochemical assays, cellular experiments and 
colony formation assays, we demonstrated that UPP is a comparable lipid phosphatase 
as PTEN.  
              To determine the distinct localization of UPP we examined the colocalization 
of UPP with different organelle markers. Data from immunofluorescence and live cell 
imaging by confocal microscopy indicated a potential function of UPP in endocytosis 
and membrane trafficking. As UPP/PTEN-long has been shown to be a membrane-
permeable lipid phosphatase that can be secreted from cells and enter neighboring 
cells (Hopkins et al., 2013), UPP might simply be a cargo protein in the endocytic 
pathway.  
              Moreover, we observed UPP co-localized with E-cadherin/β-catenin at 
adherens junctions. General investigations of PTEN localization has found its 
accumulation at cell-cell contacts and co-localization with E-cadherin/β-catenin upon 
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formation of growth-arrested structures in human mammary epithelial cells (Fournier 
et al., 2009). Change of expression of  E-cadherin is a cell surface biomarker of 
epithelial-mesenchymal transition (EMT), which is an important early event in the 
invasion and metastasis of cancer (Zeisberg and Neilson, 2009). Additionally, PTEN 
loss promoted EMT in human colon cancer cell lines HCT116 and SW480 (Bowen et 
al., 2009). Furthermore, PTEN loss has been shown to cooperate with activation of the 
RAS/MAPK pathway to induce EMT and metastasis initiated from prostate 
stem/progenitor cells (Mulholland et al., 2012).  However, those studies could not 
distinguish PTEN from UPP, and thus it is possible that UPP contributes to these 
functions.  
                  We also demonstrated that UPP is a better binding partner for IRS1, but not 
IGF1R, suggesting a differential function of UPP. The physiological significance of 
UPP should be further evaluated in UPP specific knockout cell lines or mice. 
According to the preliminary data from UPP specific knockout cells, there is no 
drastic effect on pAKT levels, suggesting endogenous UPP is not the principle lipid 
phosphatase for PIP3 in cells.  In the future, we would like to measure the protein 
phosphatase activity of UPP in vitro and in cells. Additionally, to identify novel 
functions of UPP, we could look for UPP-specific binding proteins using tandem 
affinity purification. Once we confirm the physiological function of UPP, we would 
try to identify ubiquitin E3 ligase responsible for the unique regulation of UPP.  
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CHAPTER FIVE 
MATERIALS AND METHODS 
 
MATERIALS 
 
Antibodies 
 
              p-Akt (T308) (cat#C31E5E), p-Akt (S473) (cat#D9E), Akt  (cat#40D4), p-
Erk1/2 (T202/Y204) (cat#D13.14.4E), Erk1/2 (cat#3A7), p-IGF1Rβ 
(Y1135/1136)/IRβ (Y1150/1151) (cat#19H7), p-IGF1Rβ(Y980) (Cat#4568), p-
EGFR(Y1068) (cat#2234), E-cadherin (24E10) (cat#3195), Rab5 (C8B1) Rabbit mAb 
(cat#3547), Syntaxin 6 (C34B2) (Cat# 2869) are from Cell Signaling Technology.  
              Anti-IRS-1 (pY612) (Cat# 44-816G) and anti-IRS-1(pY896) (Cat# 44818G) 
are from Invitrogen. IGF1Rβ(C-20) (Cat# sc-713), anti-PTEN (clone A2B1) (Cat# sc-
7974), p-IRS-1 (Y989) (Cat# sc-17200), NEDD4-1 (H-135) (Cat# sc-25508), and 
EGFR (1005) (Cat# sc-03) are from Santa Cruz Biotechnology.  
              Anti-IRS1 antibody (clone 4.2.2) (Cat# 05-1085), anti-IRS1 (Cat# 06-248) 
and anti-NEDD4 (Cat# 07-049) are from Millipore.  
             Anti-Mouse NEDD4 (Cat# 611480), Mouse Anti-β-Catenin (Cat# 610153), 
mouse Anti-EEA1 (Cat# 610457), Mouse Anti-cytochrome c (Cat# 556432) is from 
BD Transduction laboratories.  
 
                          
91 
 
             Anti-human PTEN (clone 6H2.1) (Cat# ABM-2052) and anti-human PTEN 
(clone 11G8.1) (Cat# ABM-2055) are from Cascade Bioscience.  
             Anti-phosphotyrosine clone PY-20 (Cat# P4110), anti-β-actin (Cat# A5316) 
and anti-γ-tubulin (clone GTU-88) (Cat# T6557) are from Sigma.  
             HA.11 clone 16B12 (Cat# MMS-101P) is from Covance.  
             Anti-α-tubulin (Cat# DM1A) is from Calbiochem.  
             Anti-KDEL, mAb (10C3) is from Enzo.  
 
Other reagents 
Mouse Insulin-like growth factor I (IGF-I) (Cat# I8779), human insulin-like growth 
factor-II (IGF-II) (cat# I2526), and human insulin (Cat# I2643) are from Sigma. 
Recombinant human epidermal growth factor (EGF) (Cat# AF-100-15) is from 
PEPROTECH. Doxycycline (Cat# 324385), and MG-132 (Cat# 474790) are from 
Calbiochem. Ubiquitin (Cat# U-100H),  KO-Ubiquitin(Cat#  UM-NOK ), Ubiquitin 
Mutant with K48 only (Cat#: UM-K480), and Ubiquitin Mutant with K63 only  (Cat#: 
UM-K630 ) were from bostonbiochem. Phosphatase inhibitor cocktail-2 (Y inhibitor) 
(Cat# P5726) for tyrosine protein phosphatases, phosphatase inhibitor cocktail-1 (Cat# 
P2850) for serine/threonine protein phosphatases, monoclonal anti-HA agarose 
conjugate clone HA-7 (Cat# A2095) and HA peptide (Cat# I2149) are from Sigma. 
IGF1Ri (OSI-906) and PI3Ki (GDC-0941) are from Selleck Chemicals; PI3Ki (BYL-
719) is from Novartis. EGFRi Erlotinib (E-4007) is from LC laboratories. AKTi-1/2/3 
(MK-2206) is from Merck. MitoTracker Red CMXRos (Cat#M-7512) is from 
 
                          
92 
 
Invitrogen. Protein A or G sepharose is from GE Healthcare. Protein A/G plus-agarose 
(Cat# sc-2003) is from Santa Cruz. S-protein agarose (Cat# 69704) is from Millipore.  
Plasmids and RNA interference 
 
                  pcDNA3.1-IRS1-HA, pcDNA3.1-IGF1Rβ-HA, pQCXIP-GFP, pQCXIP-
GFP-S-PTEN (WT/CS/GE), pQCXIP-NEDD4(WT), pQCXIP-NEDD4(CS) and 
pQCXIP-PTEN-S: For expression in cell lines, PTEN (WT/CS/GE) were subcloned 
into pQCXIP containing an N-terminal GFP and S tag. IRS1 and IGF1Rβ cDNAs 
were purchased from Addgene. For expression in 293T cells, PTEN, IRS1 and 
IGF1Rβ were subcloned into pcDNA3.1 containing a C-terminal HA tag. All the 
PTEN or IRS1 truncation mutants were amplified by PCR or two-step PCR and 
subcloned into pQCXIP with N-terminal HA tag.  
                  To make UPP construct, PTEN cDNA with 5’UTR was PCR amplified 
from human PTEN cDNA pOTB7/PTEN (open biosystems) and cloned into pQCXIP 
containing a C-terminal S tag. Different UPP mutants were created using site-directed 
mutagenesis. For UPP and PTEN imaging, UPP and PTEN were sub-cloned into 
pQCXIP with a C-terminal GFP tag. To generate Dox-inducible expression constructs, 
UPP and PTEN were sub-cloned into pLVX-Tight-Puro (Clontech) and used with 
pLVX-Tet-On Advanced to generate cell line.  
                   pLko.1-PTENi constructs: The PTEN DNA sequence used in the RNAi 
construct is CGACTTAGACTTGACCTATAT. Two-step PCRs were carried out to 
generate shRNA-resistant PTEN constructs with new sequence as 
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TGATCTCGATTTGACGTACAT. Control pLko.1-sc sequence is: 
CAACAAGATGAAGAGCACCAA. The Dox-inducible PTEN RNAi constructs were 
cloned into pLKO-Tet-On (Novartis). The sequences against mouse PTEN are: 
CGACTTAGACTTGACCTATAT and GCTAGAACTTATCAAACCCTT.  
                   The Dox-inducible RNAi constructs against mouse NEDD4, human 
NEDD4 and mouse PTEN were generated using pTRIPZ vector according to 
manufacturer’s procedure (Open biosystems). The mouse NEDD4 sequences are: 
GGAGTATATCTACCTTGTAAT and TGGGCGAGTCTTCTTCATAAA. The 
human NEDD4 sequences are: GGAGGGAACATACAAAGTATA and 
ATGGAAGAATCTTCTACATAA. The mouse PTEN sequences are: 
GCTAGAACTTATCAAACCCTT and CAGCTAAAGGTGAAGATAT. Control 
pTRIPZ-NT sequence is: CAACAAGATGAAGAGCACCAA.  
                  To knockout genes using CRISRP/Cas9, the sequences used for human 
PTEN are: CCTTTTGAAGACCATAACCCACC and 
TATCCAAACATTATTGCTATGGG. The sequences for human UPP are: 
GCTCCGGAGGCCGCCGGCGGAGG and GCGGCGGCGGCGGCACATCCAGG. 
 
Cell lines 
NEDD4
-/-
 MEFs and paired NEDD4
+/+
 MEFs were provided by Dr. Baoli Yang 
(University of Iowa). TC71, PC9, MCF7 and MDA-MB-468 were from Dr. Neal 
Rosen. 
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METHODS 
 
Western blotting 
Cells were washed twice with ice-cold phosphate-buffered saline and lysed in ice-cold 
cell lysis buffer (10mM Tris, pH7.5, 100mM NaCl, 1% Triton-X100, 0.1% SDS, 0.5% 
sodium deoxycholate, 10% glycerol, 1mM EGTA, 1mM EDTA, 0.1% 2-
mercaptoethanol and protease and phosphatase inhibitors). Equal amount of proteins 
were subjected to SDS-PAGE at 150 V and transferred to polyvinylidene difluoride 
membranes at 400 mM for 90min. The membrane is blocked with 5% milk for 30 min 
at room temperature, then washed with 3X10min with 0.1% Tween-20 in TBS (Tris 
Buffered Saline), the membrane is incubated with primary antibody diluted in 1% 
BSA in TBST for 1 hr at room temperature or overnight at 4
o
C. After washing 
3X10min with 0.1% Tween-20 in TBS, the membrane is then incubated with 
secondary antibody diluted in 1% BSA in TBST for 30-60 min at room temperature, 
washed and subjected to enhanced chemiluminescence (ECL). 
Cell culture and transfection 
Cell culture- MEFs, 293T, U2OS and PC3 were cultured in high glucose Dullbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum, 2mM L-
glutamine and penicillin-streptomycin at 37
o
C with 5% CO2. TC71 and PC9 cell lines 
were cultured in PRMI supplemented 10% FBS, L-glutamine and penicillin-
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streptomycin at 37
o
C with 5% CO2. MCF7 and MDA-MB-468 were maintained in 
DEM HG: F12 medium supplemented with 10% FBS, L-glutamine and penicillin-
streptomycin at 37
o
C with 5% CO2.  Transfections were carried out with 
Lipofectamine 2000 following the instruction manual, or with 1mg/ml PEI (DNA: 
PEI=1:3). For MCF7, transfection was performed by electroporation, using Amaxa 
cell line Nucleotector kit V. 
Co-immunoprecipitations 
 
Following indicated treatments in individual experiments, cells grown in 10-cm plates 
were placed on ice and washed with ice-cold PBS, followed by lysis in IP buffer (50 
mM HEPES, pH7.4, 150 mM NaCl, 1 mM EDTA, 0.5 mM DTT, 10% glycerol, 0.5% 
Triton-X100) plus protease inhibitors, phosphatase inhibitors and 25 M MG132. 
Lysates were then centrifuged at 4
o
C for 10 min. Clarified lysates were then incubated 
with S-protein agarose (EMD, Cat# 69704-3) pre-washed in IP buffer overnight with 
rotation at 4
o
C. Beads were then washed five times with IP buffer, eluted in 1 x SDS-
sample buffer and analyzed by immunoblot. For endogenous PTEN IP, cell lysates 
were incubated with anti-human PTEN (clone 6H2.1) overnight at 4
o
C. Then protein-
G Sepharose (GE Healthcare, Cat# 17-0618-01) was added and incubated for 3 hrs at 
4
o
C, washed with IP buffer for three times and eluted with 1 x SDS-sample buffer.  
 
Subcellular fractionation 
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Harvest 5 million cells per sample by scraping in ice-cold PBS, then resuspend cell 
pellet in hypotonic buffer ((10mM HEPES, pH7.5; 1mM DTT; 10mM NaCl; 0.1mM 
EDTA; 0.1mM EGTA; 200mM Sucrose), with phosphates, protease inhibitors and 
incubate on ice for 15min. After Freeze-thaw cycles three times, cells were further 
broken down by passing through 27G1/2 needles. Cell lysates were subjected to 
differential centrifugation: 1000g for 10min (pellet: whole cells and nucleus), then 
12,000 g for 10 min (pellet: heavy membrane including mitochondria and lysosome), 
then 100,000 g for 2 hours (pellet: light membrane including microsome and other 
small vesicles), supernatant includes cytosol fraction. For each pellet, wash with PBS 
twice before resuspend in extraction buffer. 
 
Recombinant PTEN and NEDD4 protein preparation 
 
For recombinant protein expression, PTEN (WT/C124S/G129E) or NEDD4 were 
subcloned into pFastBac containing N-terminal His tag and UPP was subcloned into 
pFastBac containing C-terminal His tag. Recombinant PTEN, NEDD4 and UPP 
proteins were expressed in Sf9 cells using the Bac-to-Bac expression system from 
Invitrogen. Cell pellets were re-suspended in Buffer A (20 mM Tris-HCl, pH7.5, 50 
mM NaCl, 1 mM DTT) and purified by Ni-NTA affinity chromatography according to 
standard procedures. Following extensive washing, proteins were eluted stepwise in 
Buffer A containing 10-250 mM imidazole. Pure fractions were pooled and dialyzed 
in 25 mM Tris, pH 7.5, 100 mM NaCl and 1 mM DTT. PTEN Proteins were further 
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purified by gel filtration (Superdex-200 column). Single peak fractions were collected, 
snap frozen and stored at -80
o
C in aliquots. 
 
In vitro PTEN ubiquitination assay 
 
The reaction was carried out at 30
oC for indicated time in a volume of 15μl containing 
50mM HEPES(pH7.5), 2mM DTT, 5mM MgCl2, 10μg of wild-type ubiquitin, K48-
Ub, K63-Ub or ko-Ub (Boston Biochem) as indicated, 50nM hE1, 1μM UbCH5c, 
5mM ATP, 50ng of recombinant HA-tagged PTEN, 1μM purified rNEDD4-1 from 
baculovirus-infected insect cells. The reaction was then stopped by adding 5μl of 
4XSDS/PAGE sample buffer and boiled for 5 min. The samples were then resolved by 
SDS/8% PAGE and the ubiquitinated PTEN species were detected by western blotting 
using HA tag.  
 
In vitro Lipid phosphatase assay 
 
Soluble di-C8-D-myo-Phosphatidylinositol 3,4,5 trisphosphate (PIP3) was purchased 
from Echelon and diluted to 0.1 mM in a phosphate-free buffer (20 mM HEPES, pH 
7.4, 1 mM EGTA). Then phospholipid vesicles (PLV) were prepared by sonication of 
0.1 mM diC8PIP3 and 0.5 mM DOPS (Sigma # P-1060). In a 25-l final volume (100 
mM Tris-HCl, pH 8.0, 2 mM DTT), indicated amounts of purified PTEN recombinant 
proteins were incubated with 10 µl of PLV (thus final diC8PIP3 concentration was 40 
M), for 15 min at 37°C. 100 µl of Malachite Green solution were added to terminate 
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the enzyme reaction and incubated for 20 minutes at room temperature. The released 
phosphate was measured by absorption at 620 nm.  
 
In vitro PTEN protein phosphatase assay 
 
To prepare p-IRS-1 and p-IGF1R, HEK293T cells were co-transfected with IRS-1-
HA/IGF1R-HA, serum starved and then stimulated with 100 ng/ml IGF1 for 10 min. 
After cells were lysed in cell lysis buffer (10 mM Tris, pH7.4, 100 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton-X 100, 10% 
glycerol) containing protease inhibitors and phosphatase inhibitors, tyrosyl-
phosphorylated IRS-1 and IGF1R were immunoprecipitated from the lysates using 
anti-HA agarose beads overnight with rotation at 4
o
C. Beads were thrice washed in 
cell lysis buffer, then washed with phosphatase assay buffer (20 mM HEPES, pH7.5, 
50 mM NaCl, 5 mM MgCl2, 1mM DTT, 0.1% NP40). IRS-1-HA and IGF1R-HA were 
then eluted in phosphatase assay buffer containing 100 μg/ml HA peptide for 30 min 
at 4
o
C. The eluant was incubated with indicated recombinant PTEN protein in the 
absence or presence of phosphatase inhibitor cocktail-2 (Y inhibitor) at 30
o
C for 1 hr. 
The reaction was terminated by adding SDS sample buffer, boiling for 5 min, and 
subjecting to immunoblotting.  
 
Cellular PI(3,4,5)P3 measurement 
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Cellular PtdInsP3 content was measured using PI3 kinase homogenous cell-based 
assay kit TR-FRET (Millipore, Cat#17-494). Lipids were extracted from 2X10
6
 PC3 
cells and cellular PIP3 level was detected following the instruction manual.  
 
Cell growth assay and colony formation assay 
 
For cell growth assay, 2x10
4 
TC71 or 5x10
4 
PC9 cells were seeded in 6-well plates. 
Twenty-four hours later, 1 g/ml Dox was added to the cells. Then cells were 
trypsinized and counted after indicated days of culture. For colony formation assay, 
2x10
3 
TC71, 1x10
3 
PC9 or 1x10
3 
PC3 cells were seeded in 6-well plates; 24-hr later 
cells were treated with 1 g/ml Dox in fresh growth media for 2 weeks. To visualize 
cell colonies, cells were fixed with 3.7% formaldehyde and stained with Giemsa stain 
(Sigma). 
 
Glucose metabolism 
 
MEFs with inducible NEDD4 shRNA (shN4-A) were treated with or without 1 g/ml 
Dox for 2 days, then 1.5x10
5
 cells were seeded in 6-well plates, serum-starved for 6 
hrs, and then stimulated with 200 ng/ml insulin for 18 hours. Conditioned media were 
taken before and after insulin treatment. Concentration of glucose, lactate, glutamine 
and glutamate in the media were measured using an YSI 7100 nutrient analyzer (YSI 
Life Sciences). Rates of consumption or secretion were calculated, normalizing to cell 
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numbers (average of the starting and final cell numbers). Statistical significance was 
determined using a one-tailed student’s t test.  
Microscopy and live cell imaging 
For fluorescence analysis, cells were grown stably on glass coverslips in a six-well 
plate. After 24 hrs, treated cells were then fixed with 3.7% paraformaldehyde in 
20mM HEPES pH7.5 for 20min at room temperature, followed by permeabilization in 
0.2% Triton in PBS for 5min. Slides were then incubated with primary antibodies in 
blocking buffer (PBS supplemented with 1% BSA) at room temperature for 1hr or at 4 
degree for overnight followed by incubation with Alexa Fluo secondary antibodies 
(Invitrogen) for 30 min at room temperature. After extensive washing, coverslips were 
mounted on microscope slides and visualized with a Nikon Eclipse Ti-U confocal 
microscope using a x20 or x60 objective. Images were acquired using Nikon EZ-C1 
image acquisition software and edited using Photoshop. For live cell imaging cells 
were grown in 35 mm glass bottom dishes (MatTek) and imaged using an Ultraview 
Vox (Perkin Elmer) spinning disc confocal with a Nikon Ti-E microscope, 
Hamamatsu C9100-13 EMCCD camera, heated incubation chamber with CO2 and 
Volocity image acquisition software (Improvision). 
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